<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">New Horiz Transl Med</journal-id>
<journal-id journal-id-type="iso-abbrev">New Horiz Transl Med</journal-id>
<journal-title-group>
<journal-title>New Horizons in Translational Medicine</journal-title>
</journal-title-group>
<issn pub-type="ppub">2352-7536</issn>
<issn pub-type="epub">2307-5023</issn>
<publisher>
<publisher-name>Elsevier Ltd</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">29094062</article-id>
<article-id pub-id-type="pmc">5653644</article-id>
<article-id pub-id-type="publisher-id">S2307-5023(17)30021-8</article-id>
<article-id pub-id-type="doi">10.1016/j.nhtm.2017.06.001</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Metabolomics for the masses: The future of metabolomics in a personalized world</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Trivedi</surname>
<given-names>Drupad K.</given-names>
</name>
<xref ref-type="fn" rid="fn1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hollywood</surname>
<given-names>Katherine A.</given-names>
</name>
<xref ref-type="fn" rid="fn1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Goodacre</surname>
<given-names>Royston</given-names>
</name>
<email>roy.goodacre@manchester.ac.uk</email>
<xref ref-type="corresp" rid="cor1">⁎</xref>
</contrib>
</contrib-group>
<aff id="aff0005">Manchester Institute of Biotechnology and School of Chemistry, University of Manchester, 131 Princess Street, Manchester M1 7DN, UK</aff>
<author-notes>
<corresp id="cor1"><label>⁎</label>Corresponding author. <email>roy.goodacre@manchester.ac.uk</email></corresp>
<fn id="fn1">
<label>1</label>
<p id="ntp0005">These authors contributed equally to production of this manuscript.</p>
</fn>
</author-notes>
<pub-date pub-type="pmc-release">
<day>1</day>
<month>3</month>
<year>2017</year>
</pub-date>
<!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="ppub">.-->
<pub-date pub-type="ppub">
<month>3</month>
<year>2017</year>
</pub-date>
<volume>3</volume>
<issue>6</issue>
<fpage>294</fpage>
<lpage>305</lpage>
<history>
<date date-type="received">
<day>25</day>
<month>5</month>
<year>2017</year>
</date>
<date date-type="rev-recd">
<day>2</day>
<month>6</month>
<year>2017</year>
</date>
<date date-type="accepted">
<day>2</day>
<month>6</month>
<year>2017</year>
</date>
</history>
<permissions>
<copyright-statement>© 2017 The Authors</copyright-statement>
<copyright-year>2017</copyright-year>
<license license-type="CC BY" xlink:href="http://creativecommons.org/licenses/by/4.0/">
<license-p>This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).</license-p>
</license>
</permissions>
<abstract id="ab0010">
<p>Current clinical practices focus on a small number of biochemical directly related to the pathophysiology with patients and thus only describe a very limited metabolome of a patient and fail to consider the interations of these small molecules. This lack of extended information may prevent clinicians from making the best possible therapeutic interventions in sufficient time to improve patient care. Various post-genomics ‘(’omic)’ approaches have been used for therapeutic interventions previously. Metabolomics now a well-established’omics approach, has been widely adopted as a novel approach for biomarker discovery and in tandem with genomics (especially SNPs and GWAS) has the potential for providing systemic understanding of the underlying causes of pathology. In this review, we discuss the relevance of metabolomics approaches in clinical sciences and its potential for biomarker discovery which may help guide clinical interventions. Although a powerful and potentially high throughput approach for biomarker discovery at the molecular level, true translation of metabolomics into clinics is an extremely slow process. Quicker adaptation of biomarkers discovered using metabolomics can be possible with novel portable and wearable technologies aided by clever data mining, as well as deep learning and artificial intelligence; we shall also discuss this with an eye to the future of precision medicine where metabolomics can be delivered to the masses.</p>
</abstract>
</article-meta>
</front>
<body>
<sec id="s0005">
<label>1</label>
<title>Introduction</title>
<p>Central to this review is the role of metabolomics within the clinical sciences and so metabolomics as a discipline is first introduced, along with the role of clinically useful biomarkers (small molecules). Following this we discuss metabolomics approaches for personalised and precision medicine and the future role of delivering metabolomics to the masses.</p>
<p>Whilst there are many definitions of metabolomics we consider that metabolomics is a multidisciplinary science that seeks to define the entire complement of small molecular weight molecules termed metabolites within a biological matrix of interest. Metabolomics has been readily applied to a vast array of biological matrices of pre-clinical and clinical medicine relevance, with perhaps not surprisingly the most common being blood plasma and serum as well as urine. These are not the only samples accessible to the clinician and many studies have also focussed on extending these measurements towards intact tissues. This is particularly important for cancer diagnostics as measuring the pathology directly is likely to yield pathophysiological information about the disease (<italic>i.e.</italic> the cause) rather than measuring circulating metabolites (<italic>i.e.</italic> the likely downstream effect). In addition, studies have also shown that it is possible to generate information-rich metabolomes from human saliva, breath, cerebrospinal fluid (CSF), broncho alveolar lavage (BAL), sweat, faeces (as well as other locations in the gastro-intestinal tract), semen, and amniotic fluid. Finally, some research has also cultured primary cells for mammalian cell-based models, which may be particularly important for ADME-Tox (adsorption, distribution, metabolism and excretion-toxicology) studies.</p>
<p>The term metabolomics was first coined in the late 1990s <xref ref-type="bibr" rid="bib1">[1]</xref> and had its 18th anniversary last year <xref ref-type="bibr" rid="bib2">[2]</xref>. Metabolomics has increased in popularity and applicability ever since. Metabolomics can no longer be described as a novel concept within the clinical arena and it is now emergent. A simple search of Web of Science (on 7th Feb 2017) for (metabolom* OR metabonom*) AND (clinical OR medicine) within the research topic field returns over 3700 articles. Within the range of ‘omic approaches (<italic>i.e.</italic> transcriptome, proteome) the metabolome is perhaps the most closely linked to the phenotype of the subject and thus, can report on disease status as well as the effect and response to external stimuli (<italic>e.g</italic>. drug therapy, nutrition, exercise, <italic>etc</italic>).</p>
</sec>
<sec id="s0010">
<label>2</label>
<title>The role of biomarkers in clinics</title>
<p>To treat disease GPs, clinicians and health workers require diagnostic indicators of disease, which can be used not only to diagnose said disease but also to assess the applicability of therapeutic interventions. These indicators are referred to as biomarkers and the NIH definition of a biomarker is <xref ref-type="bibr" rid="bib3">[3]</xref>:<disp-quote><p>“A characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention.”</p></disp-quote></p>
<p>The use of biomarkers to direct therapeutic intervention in terms of whether dietary and lifestyle interventions are necessary, or whether drugs are appropriate or if surgery is needed, is highlighted in <xref ref-type="fig" rid="f0005">Fig. 1</xref>.<fig id="f0005"><label>Fig. 1</label><caption><p>Figure illustrating disease progression (left hand side) along with the role of biomarkers on disease (right hand side) and how these may inform a range of personalised interventions.</p></caption><alt-text id="at0005">Fig. 1</alt-text><graphic xlink:href="gr1"></graphic></fig></p>
<p>A summary of clinically useful biomarkers used in clinical practice are provided in <xref ref-type="table" rid="t0005">Table 1</xref> (summarised from a test catalogue provided by Mayo Clinic, US available at <ext-link ext-link-type="uri" id="ir0005" xlink:href="http://www.mayomedicallaboratories.com">http://www.mayomedicallaboratories.com</ext-link>). Whilst these biomarkers are very valuable for diagnosing disease there is an urgent need to have many more that are highly predictive and robust. There are many more biomarkers waiting to be discovered and this is a very active area of research in metabolomics.<table-wrap id="t0005" position="float"><label>Table 1</label><caption><p>A selection of small molecule biomarkers and their clinical relevance; summarised from an available test list at the Mayo Clinic, US. The biological matrix investigated (U- urine, P-plasma, Sm-serum, Sa-saliva, Se-semen, WB-whole blood, BS-dried blood spot &amp; C-CSF) and the analytical method/test applied is detailed.</p></caption><alt-text id="at0030">Table 1</alt-text><table frame="hsides" rules="groups"><tbody><tr><td><inline-graphic xlink:href="fx1.gif"><alt-text id="at0035">Image 1</alt-text></inline-graphic></td></tr></tbody></table></table-wrap></p>
</sec>
<sec id="s0015">
<label>3</label>
<title>Current positioning of metabolomics</title>
<p>With such popularity and regard, metabolomics as a discipline must look towards the future and begin to anticipate how the field can develop and transition into the modern-day world. As mentioned above metabolomics is now established, and whilst work is on-going in terms of technology and computational improvements, the method is now considered routine. Despite this maturity, the literature is unfortunately saturated with small-scale preliminary-type studies with many suffering from being poor in experimental design and thus any findings are likely to be false as they lack statistical robustness and validity <xref ref-type="bibr" rid="bib4">[4]</xref>. This is not a unique feature of metabolomics and as nicely exemplified by George Poste <xref ref-type="bibr" rid="bib5">[5]</xref> in his article entitled “Bring on the biomarkers”, whilst many biomarkers have been described in the academic literature comparatively few (well almost zero) have made it into the clinic. With reference to ‘omics and biomarker discovery one is often reminded of Henry Nix's famous statement <xref ref-type="bibr" rid="bib6">[6]</xref>:<disp-quote><p>“Data does not equal information; information does not equal knowledge; and, most importantly of all, knowledge does not equal wisdom. We have oceans of data, rivers of information, small puddles of knowledge, and the odd drop of wisdom.”</p></disp-quote></p>
<p>With this in mind we believe that the field must drive forward towards the undertaking of large cohort multi-centre studies to enhance the discovery of biomarkers that have increased prospects of translation into point of care and rapid diagnostics; this biomarker discovery process is highlighted in <xref ref-type="fig" rid="f0010">Fig. 2</xref>, and of course is not limited to metabolites but any molecule.<fig id="f0010"><label>Fig. 2</label><caption><p>Schematic representation of the major steps for metabolomics biomarker discover. This initially starts out with a “Discovery” phase which involves in depth metabolomics assessment in (for example) case-control for disease stratification; this tends to be done on relatively small cohorts (<italic>n</italic> = 100 s). Following this a “Pre-validation” phase then repeats this untargeted metabolomics assessment in a different patient-control cohort (also of <italic>n</italic> = 100 s and preferably from a geographically distinct area from the first discovery phase). Following this there is an analytical “Development” phase for the assessment of the biomarker(s) discovered using lower cost technologies: this represents a shift from mass spectrometry or NMR spectroscopy to targeted chromatography or direct measurements using (for example) lateral flow devices. Finally using this faster and cheaper technology there is a “Validation” phase in large patient cohorts (<italic>n</italic> = 10,000/100,000 s) to assess the robustness of the biomarker(s) discovered.</p></caption><alt-text id="at0010">Fig. 2</alt-text><graphic xlink:href="gr2"></graphic></fig></p>
<p><xref ref-type="table" rid="t0010">Table 2</xref> highlights several key metabolomics studies that have been aimed towards identifying biomarker candidates for an array of diseases. This table indicates the target disease of interest and the publication year, which illustrates the attempts made for biomarker discovery using metabolomics approaches, for a specific condition. It also summarises the number of control candidates and the number of diseased patients that were incorporated into the studies. Although these and other authors do not deliberately eschew obfuscation these numbers are often difficult to distinguish clearly within a manuscript. In addition, in some cases longitudinal studies are conducted whereby a patient is their own control. In order to have clarity in what was done within a study and what should be reported the Metabolomics Standards Initiative (MSI) initiated and subsequently published a series of papers on minimum reporting standards <xref ref-type="bibr" rid="bib7">[7]</xref>. Within <xref ref-type="table" rid="t0010">Table 2</xref> the biomarker (or biomarker panels) that have been discovered within each study are documented and, we note if an independent validation has occurred within the same study which will of course increase confidence in the validity of said biomarker.<table-wrap id="t0010" position="float"><label>Table 2</label><caption><p>Potential new metabolite biomarkers discovered and reported since 2000. Various sets of biomarkers have been proposed over the years for a number of diseases based on metabolomic investigations. Studies marked with an asterisk (*) indicates a further validation study that was included in the same publication.</p></caption><alt-text id="at0040">Table 2</alt-text><table frame="hsides" rules="groups"><thead><tr><th><bold>Disease/condition</bold></th><th><bold>Year of publication</bold></th><th><bold>Control subjects</bold></th><th><bold>Test subjects</bold></th><th><bold>Proposed biomarkers</bold></th></tr></thead><tbody><tr><td>Abnormal savda</td><td>2008 <xref ref-type="bibr" rid="bib84">[84]</xref></td><td>20</td><td>110</td><td>Glycochenodeoxycholic acid and bilirubin</td></tr><tr><td>Acute coronary syndrome</td><td>2009 <xref ref-type="bibr" rid="bib90">[90]</xref></td><td>10</td><td>19</td><td>Citric acid, 4-hydroxyproline, aspartic acid, fructose, lactate, urea, glucose and valine</td></tr><tr><td>Acute kidney injury</td><td>2012 <xref ref-type="bibr" rid="bib132">[132]</xref></td><td>17</td><td>17</td><td>Dimethylarginine, pyroglutamate, lysoPC (selection of), acylcarnitine (selection of), phenylalanine, creatinine, homocysteine, methionine, arginine, tryptophan</td></tr><tr><td>Advanced liver fibrosis</td><td>2016 <xref ref-type="bibr" rid="bib165">[165]</xref></td><td>30</td><td>27</td><td>Panel inc: choline, glucose, glutamine, cysteine, histidine, citrate, acetoacetate</td></tr><tr><td>Alzheimer's disease</td><td>2010 <xref ref-type="bibr" rid="bib99">[99]</xref></td><td>20</td><td>20</td><td>Lysophosphocholine, tryptophan, phytosphingosine, dihydrosphingosine, hexadecosphinganine</td></tr><tr><td>Alzheimer's disease</td><td>2012 <xref ref-type="bibr" rid="bib127">[127]</xref></td><td>~52</td><td>~77</td><td>Desmosterol</td></tr><tr><td>Alzheimer's disease</td><td>2014 <xref ref-type="bibr" rid="bib148">[148]</xref></td><td>57</td><td>57</td><td>Arachidonic acid, <italic>N, N</italic>-dimethylglycine, thymine, glutamine, glutamic acid, and cytidine</td></tr><tr><td>Alzheimer's disease</td><td>2014 <xref ref-type="bibr" rid="bib151">[151]</xref></td><td>15</td><td>15</td><td>Alanine and taurine</td></tr><tr><td>Alzheimer's disease</td><td>2015 <xref ref-type="bibr" rid="bib164">[164]</xref></td><td>218</td><td>256</td><td>Sphinganine−1-phosphate, ornithine, phenlyllatic acid, inosine, 3-dehydrocarnitine, hypoxanthine</td></tr><tr><td>Asthma</td><td>2011 <xref ref-type="bibr" rid="bib110">[110]</xref></td><td>42</td><td>20</td><td>Panel inc: Adenosine, alanine, carnitine, formate, fumarate, glucose, histidine, taurine, threonine, succinate</td></tr><tr><td>Asthma</td><td>2013 <xref ref-type="bibr" rid="bib139">[139]</xref></td><td>26</td><td>39</td><td>methionine, glutamine, histidine</td></tr><tr><td>Atherosclerosis</td><td>2010 <xref ref-type="bibr" rid="bib103">[103]</xref></td><td>28</td><td>16</td><td>Palmitate, stearate and 1-monolinoleolglycerol</td></tr><tr><td>Autism*</td><td>2015 <xref ref-type="bibr" rid="bib161">[161]</xref></td><td>24</td><td>22</td><td>Methylguanidine, indoxyl sulfate, glucuronic acid, desaminotyrosine, guanidiosuccinate acid</td></tr><tr><td>Autism*</td><td>2016 <xref ref-type="bibr" rid="bib169">[169]</xref></td><td>63</td><td>73</td><td>Panel inc: decanoylcarnitine, pregnanetriol, uric acid, 9,10 epoxyoctadecanoic acid, docosahexanoic acid, docosapentanoic acid</td></tr><tr><td>Bladder cancer*</td><td>2011 <xref ref-type="bibr" rid="bib125">[125]</xref></td><td>16</td><td>28</td><td>Panel of 50+ differential metabolites</td></tr><tr><td>Bladder cancer</td><td>2014 <xref ref-type="bibr" rid="bib146">[146]</xref></td><td>121</td><td>138</td><td>Succinate, pyruvate, oxoglutarate, carnitine &amp; acylcarnitines, phosphoenolpyruvate</td></tr><tr><td>Breast cancer</td><td>2010 <xref ref-type="bibr" rid="bib97">[97]</xref></td><td>50</td><td>50</td><td>Five unidentified biomarkers</td></tr><tr><td>Breast cancer</td><td>2012 <xref ref-type="bibr" rid="bib134">[134]</xref></td><td>34</td><td>80 (40 <italic>vs</italic> 40)</td><td>Palmitic acid, stearic acid, linoleic acid, FFA</td></tr><tr><td>Cardiovascular diseases</td><td>2014 <xref ref-type="bibr" rid="bib145">[145]</xref></td><td>/</td><td>67</td><td>Medium-and long-chain acylcarnitines, alanine</td></tr><tr><td>Chronic heart failure</td><td>2013 <xref ref-type="bibr" rid="bib143">[143]</xref></td><td>15</td><td>39</td><td>Lactate, creatine, glucose, glycoprotein, lipid species and amino acids</td></tr><tr><td>Chronic Hepatitis B</td><td>2006 <xref ref-type="bibr" rid="bib73">[73]</xref></td><td>50</td><td>37</td><td>Lysophosphatidyl choline and glycochenodeoxycholic acid</td></tr><tr><td>Chronic kidney disease</td><td>2011 <xref ref-type="bibr" rid="bib120">[120]</xref></td><td>13</td><td>18</td><td>Urinary neutrophil gelatinase-associated lipocalin</td></tr><tr><td>Chronic widespread musculoskeletal pain</td><td>2015 <xref ref-type="bibr" rid="bib160">[160]</xref></td><td>3736</td><td>1191</td><td>Epiandrosterone sulfate, dehydroisoandrosterone sulfate, androsterone sulfate, 3-(4-hydroxyphenyl) acetate, nonadecanoate</td></tr><tr><td>Colorectal cancer staging</td><td>2009 <xref ref-type="bibr" rid="bib87">[87]</xref></td><td>–</td><td>31</td><td>Panel inc: fatty acids, organic acids, sugars, steroid, fatty acid ester and pyrimidine nucleoside.</td></tr><tr><td>Colorectal cancer*</td><td>2010 <xref ref-type="bibr" rid="bib94">[94]</xref></td><td>110</td><td>112</td><td>Hydroxylated, polyunsaturated ultra-long-chain fatty acids</td></tr><tr><td>Colorectal cancer</td><td>2011 <xref ref-type="bibr" rid="bib117">[117]</xref></td><td>8</td><td>42</td><td>Free fatty acids and esterified fatty acids</td></tr><tr><td>Colorectal cancer</td><td>2016 <xref ref-type="bibr" rid="bib170">[170]</xref></td><td>254</td><td>320 (31)</td><td>Panel inc: octadecanoic acid, lactic acid, threonic acid, 3-hydroxy butanoic acid, serine, cysteine</td></tr><tr><td>Coronary artery disease</td><td>2012 <xref ref-type="bibr" rid="bib126">[126]</xref></td><td></td><td>2023</td><td>Dicarboxylacylcarnitines, medium-chain acylcarnitines, fatty acids</td></tr><tr><td>Coronary heart disease</td><td>2009 <xref ref-type="bibr" rid="bib88">[88]</xref></td><td>25</td><td>23</td><td>Saturated fatty acids, trans-fatty acid, n3 and n6 poly unsaturated fatty acids</td></tr><tr><td>Coronary heart disease*</td><td>2014 <xref ref-type="bibr" rid="bib41">[41]</xref></td><td>897</td><td>131</td><td>LysoPC (18:1), LysoPC (18:2), MG (18:2), SM (28:1)</td></tr><tr><td>Diabetes</td><td>2010 <xref ref-type="bibr" rid="bib106">[106]</xref></td><td>60</td><td>40</td><td>3-indoxyl sulfate, glycerophospholipids, free fatty acids and bile acids</td></tr><tr><td>Diabetic kidney disease</td><td>2012 <xref ref-type="bibr" rid="bib128">[128]</xref></td><td></td><td>52 (26 <italic>vs</italic> 26)</td><td>Acyl-carnitines, acyl-glycine and metabolites related to tryptophan metabolism</td></tr><tr><td>Diabetic mellitus and diabetic nephropathy</td><td>2011 <xref ref-type="bibr" rid="bib111">[111]</xref></td><td>30</td><td>120</td><td>Non-esterified fatty acids and esterified fatty acids</td></tr><tr><td>Diabetic nephropathy and type 2 diabetes</td><td>2009 <xref ref-type="bibr" rid="bib93">[93]</xref></td><td>25</td><td>41</td><td>Phytospingosine, glycine, lysine, dihydrosphingosine, leucine</td></tr><tr><td>Disorders of Propionate Metabolism*</td><td>2007 <xref ref-type="bibr" rid="bib78">[78]</xref></td><td>10</td><td>9</td><td>Propionyl carnitine, unsaturated acylcarnitine, γ-butyrobetaine, siovaleryl carnitine</td></tr><tr><td>Down syndrome</td><td>2015 <xref ref-type="bibr" rid="bib159">[159]</xref></td><td>93</td><td>23</td><td>Progesterone and dihydrouracil</td></tr><tr><td>Endometrial carcinoma</td><td>2016 <xref ref-type="bibr" rid="bib173">[173]</xref></td><td>25</td><td>25(10)</td><td>Porphobilinogen, acetlycysteine, <italic>n</italic>-acetylserine, urocanic acid, isobutylglycine</td></tr><tr><td>Gastric cancer</td><td>2016 <xref ref-type="bibr" rid="bib166">[166]</xref></td><td>40</td><td>83</td><td>Sucrose, dimethylamine, 1-methylnicotinamide, 2-furoylglycine, <italic>N-</italic>acetyl- serotonin, trans-aconitate, alanine, formate, and serotonin</td></tr><tr><td>Gastrointestinal cancer</td><td>2012 <xref ref-type="bibr" rid="bib129">[129]</xref></td><td>12</td><td>38</td><td>3-hydroxypropionic acid, pyruvic acid, <sc>L</sc>-alanine, glucuronolactone, <sc>L</sc>-glutamine</td></tr><tr><td>Healthy plasma metabolome</td><td>2008 <xref ref-type="bibr" rid="bib81">[81]</xref></td><td>269</td><td>–</td><td>300+ unique compounds</td></tr><tr><td>Hepatitis B*</td><td>2013 <xref ref-type="bibr" rid="bib140">[140]</xref></td><td>11</td><td>13</td><td>Tyrosinamide, biotin sulfone, hexanoic acid, 1-aminonaphthalene, 7-dehydroxycholesterol, azelaic acid</td></tr><tr><td>Hepatitis E and Hepatitis B</td><td>2011 <xref ref-type="bibr" rid="bib119">[119]</xref></td><td>18</td><td>32</td><td>Panel inc: <sc>L</sc>-proline, <sc>L</sc>-isoleucine, acetone, glycerol, glycine, biopterine, adenosine</td></tr><tr><td>Hepatocarcinoma</td><td>2011 <xref ref-type="bibr" rid="bib121">[121]</xref></td><td>38</td><td>41</td><td>1-methyladenosine</td></tr><tr><td>Hepatocellular carcinoma</td><td>2009 <xref ref-type="bibr" rid="bib92">[92]</xref></td><td>20</td><td>20</td><td>Panel of 18 metabolites inc: glycine, urea, threonine</td></tr><tr><td>High altitude pulmonary edema*</td><td>2015 <xref ref-type="bibr" rid="bib162">[162]</xref></td><td>35</td><td>35</td><td>Methionine, hypoxanthine, inosine, sphingosine, palmitoyl carnitine, C8 carnitine</td></tr><tr><td>Human hepatocellular carcinoma</td><td>2011 <xref ref-type="bibr" rid="bib116">[116]</xref></td><td>71</td><td>106</td><td>Bile acids, histidine, inosine, glycochenodeoxychoclic acid, glycocholic acid, taurocholic acid and chenodeoxycholic acid</td></tr><tr><td>Interstitial cystitis</td><td>2016 <xref ref-type="bibr" rid="bib172">[172]</xref></td><td>21</td><td>42</td><td>Oleic acid, 2-deoxytetronic acid, saccharic acid, phosphate, trehalose, erthronic acid, oxalic acid, sulfuric acid, cystine, lyxitol, lysine, histidine</td></tr><tr><td>Intestinal fistulas</td><td>2006 <xref ref-type="bibr" rid="bib76">[76]</xref></td><td>17</td><td>40</td><td>Glycochenodeoxycholic acid, glycodeoxycholic acid, taurochenodexycholic acid, taurodeoxycholic acid, lysophosphatidyl choline (C16: 0 and C18:2), phenylalanine, tryptophan and carnitine</td></tr><tr><td>IVF</td><td>2008 <xref ref-type="bibr" rid="bib85">[85]</xref></td><td>17</td><td>17</td><td>Glutamate and alanine/lactate ratios</td></tr><tr><td>Lepromatous leprosy</td><td>2011 <xref ref-type="bibr" rid="bib118">[118]</xref></td><td>10</td><td>13</td><td>Eicosapentaenoic acid, docosahexaenoic acid and arachidonic acid</td></tr><tr><td>Liver cirrhosis</td><td>2011 <xref ref-type="bibr" rid="bib113">[113]</xref></td><td>22</td><td>37</td><td>Lysophosphatidyl cholines, bile acids, hypoxanthine, stearamide, oleamide, myristamide</td></tr><tr><td>Liver failure due to Hepatitis B</td><td>2010 <xref ref-type="bibr" rid="bib104">[104]</xref></td><td>16</td><td>26</td><td>1-Lioleoylglycerophosphocholine or 1-linoleoylphosphatidylcholine</td></tr><tr><td>Lung cancer</td><td>2010 <xref ref-type="bibr" rid="bib108">[108]</xref></td><td>12</td><td>12</td><td>Lysophosphatidylcholines: lyso16:0, sn−2 lysoPC 16:0, sn−1 lysoPC 18:0, sn−1 lysoPC 18:1 and sn−1 lysoPC 18:2</td></tr><tr><td>Lung cancer</td><td>2011 <xref ref-type="bibr" rid="bib122">[122]</xref></td><td>29</td><td>33</td><td>A panel of 23 serum metabolites and 48 tissue specific metabolites</td></tr><tr><td>Lung cancer*</td><td>2014 <xref ref-type="bibr" rid="bib149">[149]</xref></td><td>536</td><td>469</td><td>Creatine riboside, cortisol sulfate, <italic>N</italic>-acetylneuraminic acid</td></tr><tr><td>Lung cancer*</td><td>2015 <xref ref-type="bibr" rid="bib157">[157]</xref></td><td>20</td><td>18</td><td>Maltose, ethanolamine, glycerol, palmitic acid, lactic acid,</td></tr><tr><td>Lung cancer</td><td>2015 <xref ref-type="bibr" rid="bib155">[155]</xref></td><td>55</td><td>41</td><td>Panel inc: trisaccharide phosphate, trihexose, nonanedioic acid, MG (22:2), tetrahexose</td></tr><tr><td>Lung cancer</td><td>2016 <xref ref-type="bibr" rid="bib167">[167]</xref></td><td>34</td><td>23 (11)</td><td>Isobutyl decanoate, putrescine, diethyl glutarate, cysteamine</td></tr><tr><td>Major depressive disorder</td><td>2012 <xref ref-type="bibr" rid="bib135">[135]</xref></td><td>25</td><td>26</td><td>Tryptophan, GABA and lysine</td></tr><tr><td>Major depressive disorder*</td><td>2015 <xref ref-type="bibr" rid="bib153">[153]</xref></td><td>59</td><td>60</td><td>Acyl carnitines, lipid metabolism and tryptophan</td></tr><tr><td>Malignant adrenal tumours</td><td>2011 <xref ref-type="bibr" rid="bib124">[124]</xref></td><td>45</td><td>102</td><td>Panel inc: metabolites from steroid metabolism pathways</td></tr><tr><td>Malignant Oligodendroglioma*</td><td>2008 <xref ref-type="bibr" rid="bib83">[83]</xref></td><td>10</td><td>24</td><td>Alanine, lipids, valine, the total choline compounds, proline, myoinositol, taurine, glutamine, glutamate, GABA, NAA, acetate, and creatine</td></tr><tr><td>Melamine-induced nephrolithiasis</td><td>2011 <xref ref-type="bibr" rid="bib123">[123]</xref></td><td>74</td><td>73</td><td>Proline, 5C-aglycone and hypoxanthine</td></tr><tr><td>Multiple sclerosis</td><td>2014 <xref ref-type="bibr" rid="bib150">[150]</xref></td><td>17</td><td>15</td><td>Choline, myo-inositol, threonate</td></tr><tr><td>Multiple sclerosis</td><td>2015 <xref ref-type="bibr" rid="bib156">[156]</xref></td><td>12</td><td>13</td><td>LPC (18:1), LPC (18:0), LPI (16:0), Glutamate</td></tr><tr><td>Muscle respiratory chain deficiencies</td><td>2015 <xref ref-type="bibr" rid="bib163">[163]</xref></td><td>13</td><td>24</td><td>AMP, <italic>n</italic>-acetyl asparagine, oxoglutaric acid, <italic>n</italic>-succinyl-L-L2.6 diaminopimelate</td></tr><tr><td>Nasopharyngeal carcinoma</td><td>2011 <xref ref-type="bibr" rid="bib115">[115]</xref></td><td>40</td><td>37</td><td>Kynurenine<italic>, N</italic>-acetylglucosaminylamine, <italic>N</italic>-acetylglucosamine and hydroxyphenylpyruvate</td></tr><tr><td>Oesophageal cancer</td><td>2013 <xref ref-type="bibr" rid="bib141">[141]</xref></td><td>26</td><td>89</td><td>Formate, acetate, short-chain fatty acids, GABA</td></tr><tr><td>Oesophageal squamous-cell carcinoma</td><td>2013 <xref ref-type="bibr" rid="bib144">[144]</xref></td><td>53</td><td>53</td><td>Phosphatidylserines, 12-oxo−20-dihydroxy-leukotriene B4, sphinganine 1-phosphate, LysoPC, phosphatidyl ethanolamine, phosphatidyl choline</td></tr><tr><td>Onchocerciasis*</td><td>2010 <xref ref-type="bibr" rid="bib105">[105]</xref></td><td>56</td><td>76</td><td>Panel of 14 inc: hexacosenoic acid, fatty acids, proteins, sterol lipids and phosphorylated sphingolipids</td></tr><tr><td>Oral cancer</td><td>2014 <xref ref-type="bibr" rid="bib152">[152]</xref></td><td>50</td><td>30</td><td>Phenylalanine &amp; leucine</td></tr><tr><td>Oral, breast and pancreatic cancer</td><td>2010 <xref ref-type="bibr" rid="bib95">[95]</xref></td><td>87</td><td>128</td><td>betaine, choline, carnitine, glycerophosphocholine, cadaverine, putrescine, hypoxanthine, ethanolamine, trimethylamine and amino acids</td></tr><tr><td>Osteoarthritis*</td><td>2010 <xref ref-type="bibr" rid="bib98">[98]</xref></td><td>299</td><td>123</td><td>Valine to histidine ratio and leucine to histidine ratio</td></tr><tr><td>Ovarian cancer</td><td>2011 <xref ref-type="bibr" rid="bib112">[112]</xref></td><td>27</td><td>57</td><td>27-nor−5-beta-cholestane−3,7,12,24,25 pentol glucuronide</td></tr><tr><td>Ovarian cancer</td><td>2011 <xref ref-type="bibr" rid="bib114">[114]</xref></td><td>12</td><td>18</td><td><italic>N-</italic>acetylasparate and <italic>N-</italic>acetyl-aspartyl-glutamate</td></tr><tr><td>Ovarian cancer*</td><td>2012 <xref ref-type="bibr" rid="bib131">[131]</xref></td><td>50</td><td>50</td><td>2-piperidinone, <sc>L</sc>-tryptophan, lysoPC (18:3), lysoPC (14:0)</td></tr><tr><td>Ovarian endometriosis</td><td>2012 <xref ref-type="bibr" rid="bib133">[133]</xref></td><td>52</td><td>40</td><td>Sphingomyelins and phosphatidylcholines</td></tr><tr><td>Paediatric acute liver failure</td><td>2009 <xref ref-type="bibr" rid="bib89">[89]</xref></td><td>20</td><td>20</td><td>α-NH2-butyric-acid (Aab) and Aab: leucine ratio</td></tr><tr><td>Pancreatic cancer</td><td>2016 <xref ref-type="bibr" rid="bib168">[168]</xref></td><td>40</td><td>40</td><td>Panel inc: palmitic acid, 1,2 dioeoyl GLP Na2, lanosterol, lignorceric acid, 1 oleoyl rac GL, chol epoxide, erucic acid</td></tr><tr><td>Parkinson's disease</td><td>2008 <xref ref-type="bibr" rid="bib79">[79]</xref></td><td>25</td><td>66</td><td>Uric acid and glutathione</td></tr><tr><td>Parkinson's disease</td><td>2009 <xref ref-type="bibr" rid="bib91">[91]</xref></td><td>37</td><td>43</td><td>Pyruvate</td></tr><tr><td>Parkinson's disease</td><td>2015 <xref ref-type="bibr" rid="bib158">[158]</xref></td><td>104</td><td>297</td><td>Cortisol, 11-deocycortisol, 21-deoxycortisol, histidine, urocanic acid, imadazoleacetic acid, hydroxyphenylacetic acid</td></tr><tr><td>Periodontal disease</td><td>2010 <xref ref-type="bibr" rid="bib101">[101]</xref></td><td>21</td><td>18</td><td>Inosine, lysine, putrescine and xanthine</td></tr><tr><td>Pre-eclampsia</td><td>2005 <xref ref-type="bibr" rid="bib72">[72]</xref></td><td>87</td><td>87</td><td>Three unidentified molecules</td></tr><tr><td>Pre-eclampsia</td><td>2017 <xref ref-type="bibr" rid="bib174">[174]</xref></td><td>20</td><td>20</td><td>Panel inc: PC (14:0/0:0), proline betaine, proline</td></tr><tr><td>Premature labour*</td><td>2010 <xref ref-type="bibr" rid="bib107">[107]</xref></td><td>16</td><td>39</td><td>Panel inc: Methyladenine, heptanedioic acid, <italic>N-</italic>acetylglutamine, glycerol, succinic acid, mannose</td></tr><tr><td>Prostate cancer</td><td>2010 <xref ref-type="bibr" rid="bib96">[96]</xref></td><td>30</td><td>40</td><td>Acylcarnitine and arachidonoyl amine</td></tr><tr><td>Prostate cancer</td><td>2013 <xref ref-type="bibr" rid="bib138">[138]</xref></td><td>178</td><td>331</td><td>Panel of 25 metabolites inc top 5: histidine, glycine, alanine, kynurenine, glutamate &amp; glycerol−3-phosphate</td></tr><tr><td>Psoriasis</td><td>2017 <xref ref-type="bibr" rid="bib175">[175]</xref></td><td>15</td><td>14</td><td>Asparagine, aspartic acid, isoleucine, phenylalanine, ornithine, proline, lactic acid &amp; urea</td></tr><tr><td>Rectal cancer</td><td>2013 <xref ref-type="bibr" rid="bib142">[142]</xref></td><td>43</td><td>127</td><td>Lactate, threonine, acetate, glutathione, uracil, succinate, serine, formate, lysine and tyrosine</td></tr><tr><td>Renal cell carcinoma</td><td>2010 <xref ref-type="bibr" rid="bib100">[100]</xref></td><td>13</td><td>32</td><td>Panel inc: acetate, glutamate, glutamine, glucose, tyrosine, histidine, phenylalanine, formic acid, alanine, lactate</td></tr><tr><td>Rheumatoid arthritis</td><td>2010 <xref ref-type="bibr" rid="bib102">[102]</xref></td><td>51</td><td>47</td><td>Cholesterol, lactate, acetylated glycoprotein and lipids</td></tr><tr><td>Rheumatoid arthritis</td><td>2011 <xref ref-type="bibr" rid="bib109">[109]</xref></td><td>20</td><td>25</td><td>Panel inc: Glyceric acid, hypoxanthine, histidine, threonic acid, methionine, cholesterol, threonine</td></tr><tr><td>Rheumatoid arthritis</td><td>2016 <xref ref-type="bibr" rid="bib171">[171]</xref></td><td>19</td><td>46</td><td>Arginine, aspartic acid, glutamic acid, phenylalanine, serine, threonine, methlynicotinamide</td></tr><tr><td>Schizophrenia</td><td>2006 <xref ref-type="bibr" rid="bib74">[74]</xref></td><td>70</td><td>82</td><td>Citrate, glutamine, acetate, lactate</td></tr><tr><td>Schizophrenia</td><td>2007 <xref ref-type="bibr" rid="bib77">[77]</xref></td><td>–</td><td>50</td><td>50 lipids including triacylglycerols, free fatty acids, phosphatidylethanolamine.</td></tr><tr><td>Schizophrenia*</td><td>2013 <xref ref-type="bibr" rid="bib137">[137]</xref></td><td>62</td><td>62</td><td>Glycerate, eicosenoic acid, beta-hydroxybutyrate, pyruvate, cysteine</td></tr><tr><td>Systemic inflammatory response syndrome (SIRS) &amp; Sepsis</td><td>2012 <xref ref-type="bibr" rid="bib130">[130]</xref></td><td></td><td>143 (74 <italic>vs</italic> 69)</td><td>Acylcarnitines and glycerophosphatidylcholines (C10:1 and PCaaC32:0)</td></tr><tr><td>Type 2 diabetes</td><td>2006 <xref ref-type="bibr" rid="bib75">[75]</xref></td><td>45</td><td>78</td><td>Non-esterified and esterified fatty acids in plasma</td></tr><tr><td>Type 2 diabetes</td><td>2008 <xref ref-type="bibr" rid="bib80">[80]</xref></td><td>28</td><td>23</td><td>3-hydroxyhippuric acid</td></tr><tr><td>Type 2 diabetes</td><td>2008 <xref ref-type="bibr" rid="bib86">[86]</xref></td><td>time course study</td><td>75</td><td>Citrate, IL−8 and methyl-histidine and branched amino acid degradation products</td></tr><tr><td>Type 2 diabetes (T2DM) and Type 2 diabetic coronary heart diseases (T2DM-CHD)</td><td>2008 <xref ref-type="bibr" rid="bib82">[82]</xref></td><td>45</td><td>71 and 37 for T2DM &amp; T2DM-CHD</td><td>Free fatty acid (C16:0, C18:1 <italic>n</italic>−9 and C18:2 <italic>n</italic>−6)</td></tr><tr><td>Type 2 diabetes &amp; impaired fasting glucose</td><td>2013 <xref ref-type="bibr" rid="bib136">[136]</xref></td><td>1897</td><td>115 &amp; 192 respectively</td><td>Panel inc: amino acids, lipids, carbohydrates (T2D) &amp; panel of lipids, carbohydrates, amino acid plus urate &amp; erythritol (IFG)</td></tr><tr><td>Type 2 diabetes mellitus</td><td>2015 <xref ref-type="bibr" rid="bib154">[154]</xref></td><td>300</td><td>300</td><td>Lipids, hexose sugars, purine nucleotide</td></tr><tr><td>Ulcerative colitis (UC) &amp; Crohn's disease (CD)</td><td>2014 <xref ref-type="bibr" rid="bib147">[147]</xref></td><td>17</td><td>24 UC &amp; 19 CD</td><td>Panel inc: N-acetylated glycoprotein, lactate, methanol, mannose, formate</td></tr></tbody></table></table-wrap></p>
<p>It is clear from inspecting this <xref ref-type="table" rid="t0010">Table 2</xref> that there is a broad difference in the number of subjects included in these studies. The community is yet to decide what this number should be, but it should be noted and acknowledged that the availability of patients will greatly vary from disease to disease and equally access to valuable (sometimes very rare) samples will be limited. In this century alone, there have been more than 1600 publications (using a combined search of the above PLUS biomarker* from 2000 to date) that ‘claim’ to have discovered a biomarker using a metabolomics approach, which is nearly half of all papers surveyed! Although there are some exceptions, most of this research fails to acquire enough statistical power due to a limited sample size (&lt;100 subjects in total) and almost none repeat the analysis in a further cohort and thus fail to demonstrate a lack of biomarker utility. We believe that these thwart the potential translation of metabolomics research into clinics. For instance, there is minimal-known translation of metabolomics biomarker discovery into clinics for the top five causes of death in the UK (<xref ref-type="table" rid="t0015">Table 3</xref>) which include: ischaemic heart diseases, dementia and Alzheimer's disease, malignant neoplasms of trachea, bronchus and lung, chronic lower respiratory diseases and cerebrovascular diseases <xref ref-type="bibr" rid="bib8">[8]</xref>. Malignant neoplasms, respiratory disease and ischaemic heart diseases are also three of the top five leading causes of death across Europe <xref ref-type="bibr" rid="bib9">[9]</xref>.<table-wrap id="t0015" position="float"><label>Table 3</label><caption><p>Top 5 leading causes of death in men and women in England and Wales (2014).</p></caption><alt-text id="at0045">Table 3</alt-text><table frame="hsides" rules="groups"><tbody><tr><td colspan="2"><bold>Men</bold></td></tr><tr><td>Ischaemic heart diseases</td><td>36,293</td></tr><tr><td>Dementia and Alzheimer's disease</td><td>15,973</td></tr><tr><td>Malignant neoplasm of trachea, bronchus and lung</td><td>14,359</td></tr><tr><td>Chronic lower respiratory diseases</td><td>13,952</td></tr><tr><td>Cerebrovascular diseases</td><td>12,584</td></tr><tr><td colspan="2"><bold>Women</bold></td></tr><tr><td>Dementia and Alzheimer's disease</td><td>33,153</td></tr><tr><td>Ischaemic heart diseases</td><td>24,057</td></tr><tr><td>Cerebrovascular diseases</td><td>19,127</td></tr><tr><td>Chronic lower respiratory diseases</td><td>14,181</td></tr><tr><td>Malignant neoplasm of trachea, bronchus and lung</td><td>11,309</td></tr></tbody></table></table-wrap></p>
<p>Despite the above disease being of obvious importance we note the rapid rise of microorganisms as contributing to world-wide mortality. The obvious ‘culprits’ here being <italic>Mycobacterium tuberculosis</italic> and HIV, but with the almost meteoric rise in antimicrobial resistance (AMR) many normally harmless opportunistic pathogens will become increasingly important. Indeed it is predicted by 2050 that bacterial infections will kill more humans than cancer and heart disease <xref ref-type="bibr" rid="bib10">[10]</xref>. Whilst it is accepted that there are many microbial interactions with the host cell microbiome and that man is a true superorganism <xref ref-type="bibr" rid="bib11">[11]</xref> it is also notable that many common human disease may indeed have a microbial origin <xref ref-type="bibr" rid="bib12">[12]</xref>. Metabolomics is likely to play a valuable role in understanding AMR and the host-pathogen interaction.</p>
<p>This review seeks to provide an overview of metabolomics in respect to diagnostic applications and demographic screening and present a futuristic perspective on the implementation of the field with novel portable and wearable technologies.</p>
</sec>
<sec id="s0020">
<label>4</label>
<title>Is the future of healthcare simply personalized medicine?</title>
<p>Although personalised medicine is a generic entity relatively new to the field of healthcare research, it has of course been practiced for decades within a so-called evidence-based framework (<xref ref-type="fig" rid="f0015">Fig. 3</xref>). In evidence-based medicine an individual is treated for disease largely based on the most popular medicine. After the drug is taken for some time an assessment is made, with the desire to evaluate whether this has relieved symptoms (this may involve the measurement of a clinically useful biomarker (<xref ref-type="table" rid="t0005">Table 1</xref>)). Based on this deterministic assessment the patient may then stay on the same drug, be diagnosed an alternate medicine, or be given a treatment to relieve side effects of the first drug. This process is slow and potentially dangerous to the patient. A much more desirable approach is to use precision medicine and this was brought to the forefront of attention when, during his 2015 State of the Union address President Obama announced that he was launching the Precision Medicine Initiative. This was heralded as a bold new research direction <xref ref-type="bibr" rid="bib13">[13]</xref> with changing for biobank made available by NIH to support the initiative <xref ref-type="bibr" rid="bib14">[14]</xref>.<fig id="f0015"><label>Fig. 3</label><caption><p>Flow diagram illustrating personalised medicine and highlighting the differences between Evidence-based <italic>versus</italic> Precision medicine-based approaches to disease treatment. As is clear the evidence-based approach is imprecise as it relies on the patient reporting progress to therapy. By contrast, precision medicine necessitates analytical measurements on the patient – typically from genetics (<italic>viz</italic>. SNPs) and metabolomics–and then using these to direct therapy.</p></caption><alt-text id="at0015">Fig. 3</alt-text><graphic xlink:href="gr3"></graphic></fig></p>
<p>Precision medicine involves assessing the genotype (<italic>e.g.</italic> SNPs) and phenotype (<italic>e.g.</italic> metabolome) of the patient before they undergo any treatment (<xref ref-type="fig" rid="f0015">Fig. 3</xref>) and therefore relies on accurate analytical methods for directing therapy <xref ref-type="bibr" rid="bib15">[15]</xref>. Biomarkers are needed that can accurately identify the underlying pathology as these may help understand the disease aetiology and thereby result in a precise treatment <xref ref-type="bibr" rid="bib16">[16]</xref>, <xref ref-type="bibr" rid="bib17">[17]</xref>. Clearly the lack of suitable biomarkers currently holds back the wider implementation of personalised medicine <xref ref-type="bibr" rid="bib18">[18]</xref>. This is where metabolomics plays a key role as an approach to discover a biomarker, trial its detection within a large diverse population and then translate its detection into cheaper, quicker and reliable methods that could be used by a wider audience <xref ref-type="bibr" rid="bib19">[19]</xref>. As indicated above the main use of metabolomics as a tool is for biomarker discovery <xref ref-type="bibr" rid="bib20">[20]</xref>, <xref ref-type="bibr" rid="bib21">[21]</xref>, <xref ref-type="bibr" rid="bib22">[22]</xref>, <xref ref-type="bibr" rid="bib23">[23]</xref>, <xref ref-type="bibr" rid="bib24">[24]</xref>. The closest representation of a disease phenotype is a key-driving factor for the increased use of metabolomics for biomarker discovery to understand disease pathologies and finding methods of cure, and as many diseases result in changes in human metabolism it makes sense to use a method that measures metabolism directly!</p>
<p>However, the focus of biomarker discovery should not only be for pathological cures but also for preventive screening of healthy individuals (<xref ref-type="fig" rid="f0005">Fig. 1</xref>), as earlier biomarkers may be useful in directing dietary and lifestyle changes prior to more radical surgical treatment. Within biomarker discovery this raises the tantalising idea that all healthy individuals should undergo some biomarker screen well before any disease is found so that any change in a biomarker(s) level is personalised; for example, someone with an already raised PSA level may not have prostate cancer and this higher PSA levels maybe indicative of an enlarged prostate as one ages <xref ref-type="bibr" rid="bib25">[25]</xref>. Offering a well-designed screening program at a reasonable cost may not always be possible due to the numerous associated challenges; these include monetary limitations (labour and consumable costs) as well as ethical, legal and social considerations for an opt-in test. The risk-benefit ratio needs to be clearly defined per disease for a successful personalised screening <xref ref-type="bibr" rid="bib26">[26]</xref>. Encouraging biomarker discoveries from within the plasma metabolome <xref ref-type="bibr" rid="bib27">[27]</xref>, serum metabolome <xref ref-type="bibr" rid="bib28">[28]</xref>, <xref ref-type="bibr" rid="bib29">[29]</xref>, <xref ref-type="bibr" rid="bib30">[30]</xref>, <xref ref-type="bibr" rid="bib31">[31]</xref>, urinary metabolome <xref ref-type="bibr" rid="bib32">[32]</xref>, <xref ref-type="bibr" rid="bib33">[33]</xref>, <xref ref-type="bibr" rid="bib34">[34]</xref>, <xref ref-type="bibr" rid="bib35">[35]</xref> as well as the volatilome <xref ref-type="bibr" rid="bib36">[36]</xref>, <xref ref-type="bibr" rid="bib37">[37]</xref>, <xref ref-type="bibr" rid="bib38">[38]</xref> show immense potential of dramatically reducing health risks in fatal health conditions such as cancer, congenital disease, heart diseases and respiratory diseases (<xref ref-type="table" rid="t0015">Table 3</xref>). It should be noted that a key hurdle for translation of these biomarkers into a routine clinical test is the failure to <bold>validate</bold>. In the absence of a universally accepted procedure for metabolic profiling used for biomarker discovery, different sites use their own optimized procedures. Additionally, even if identical analytical platforms and routines are used, the inherent inter-laboratory variation will play a great role in detracting from the validity of a potential biomarker and there can never be certainty that the entire metabolome has been profiled with that said platform, and in fact it is accepted in the metabolomics community that there is no magic tricorder that measures everything <xref ref-type="bibr" rid="bib39">[39]</xref>. Thus, there is always a <bold>potentially</bold> ‘better’ biomarker waiting to be discovered.</p>
<p>Some notable large scale and/or multicentre metabolomics studies have been successfully conducted (<xref ref-type="table" rid="t0010">Table 2</xref>) to map the human serum metabolome <xref ref-type="bibr" rid="bib40">[40]</xref>, to identify biomarkers for incident coronary heart disease <xref ref-type="bibr" rid="bib41">[41]</xref>, and to study the response of <italic>Aspergillus nidulans</italic> to epigenetic perturbation with a hope to expedite the search for new pharmaceutical leads <xref ref-type="bibr" rid="bib42">[42]</xref>. A correct balance needs to be considered between large scale <italic>vs.</italic> small sub-population focused studies where the risk is minimal but with maximum benefits <xref ref-type="bibr" rid="bib43">[43]</xref>, <xref ref-type="bibr" rid="bib44">[44]</xref>. Due to the higher cost and effort involved in the analysis of samples by a standard metabolomics workflow, it is often tempting (albeit one could say lazy) to use a smaller sample size for biomarker discovery and pre-validation <xref ref-type="bibr" rid="bib45">[45]</xref>. However, such studies which lack the required statistical power for confident biomarker assessment will entice anyone to start designing specific assays for assessments in large cohorts (<xref ref-type="fig" rid="f0010">Fig. 2</xref>).</p>
<p>Like all ‘omics which are data rich, metabolomics on humans is influenced by many confounding factors such as age, gender, ethnicity, diet <italic>etc</italic>. <xref ref-type="bibr" rid="bib40">[40]</xref> and thus, large validation studies with suitable control cohorts must be used to remove any potential bias <xref ref-type="bibr" rid="bib4">[4]</xref>, <xref ref-type="bibr" rid="bib46">[46]</xref>. Certain metabolites that alter with normal physiological changes may also be significantly different in a metabolomics study. By way of an example, citrate has been shown to increase with age <xref ref-type="bibr" rid="bib40">[40]</xref> even in healthy individuals. A recent metabolomics study indicated amongst other metabolites that citrate was a significantly important biomarker for cancer <xref ref-type="bibr" rid="bib47">[47]</xref>. However, since an increase in citrate could also be attributed to difference in mean age (17 cancer patients = 70 and 21 healthy controls = 60) rather than altered TCA cycle in cancer, in the absence of closely age matched case-control cohort such results need to be taken with caution before inferring pathological importance of such a biomarker.</p>
<p>Whilst the current perception is that screening large control groups of healthy individuals at the same time as diseased populations is not an option for validation studies, this position must change. Indeed, many people already use wearable technology for the assessment of their exercise levels, heart rate, blood oxygen levels, as well as sleeping patterns, so collecting data on ‘healthy’ individuals is not that maverick.</p>
</sec>
<sec id="s0025">
<label>5</label>
<title>Metabolomics for the masses</title>
<p>With recent technological advancements in the form of affordable hardware (<italic>e.g.</italic> pedometers which include heart rate monitoring), health apps on smartphones, fitness bands and smart-watches, it is feasible to generate large amounts of useful health-related data even in healthy populations <xref ref-type="bibr" rid="bib48">[48]</xref>, <xref ref-type="bibr" rid="bib49">[49]</xref>. These measurements are readily available on a personalised level and could be used to complement clinical studies. For example, in treatment regimens which may include nutritional and exercise advice.</p>
<p>The tantalising question is whether metabolomics could be delivered to the masses on a personalised level? Whilst mass spectrometry linked to chromatography is a very power metabolomics platform for biomarker discovery, it is laborious and expensive and therefore unlikely to be suitable for large-scale screening of very large populations (<italic>i.e.</italic> when <italic>n</italic> &gt; 10,000, which is of course still small when we consider that the earth's population is estimated to be &gt;7.5×10<sup>9</sup>; <ext-link ext-link-type="uri" id="ir0010" xlink:href="http://www.worldometers.info/world-population/">http://www.worldometers.info/world-population/</ext-link>). Of course, once a series of biomarkers are discovered and validated the scenario is different where one now knows the measurands and these can be detected and quantified using analytical chemistry. These can include methods based on:<list list-type="simple"><list-item id="u0005"><label>•</label><p>Lateral flow devices – much like the pregnancy test which is based on antibody detection of the appropriate antigen (<italic>viz</italic>., human chorionic gonadotropin (hCG));</p></list-item><list-item id="u0010"><label>•</label><p>Dipstick approaches – for example the detection of nitrite for confirming urinary tract infections;</p></list-item><list-item id="u0015"><label>•</label><p>Breath measurements for volatiles – for example ethanol detection and quantification using fuel cells for road side testing;</p></list-item><list-item id="u0020"><label>•</label><p>Electrochemical detection – under skin glucose test is based on this and allows constant assessment of blood glucose that can be linked automatically to insulin injections <xref ref-type="bibr" rid="bib50">[50]</xref>.</p></list-item></list></p>
<p>With the above in mind emerging technologies in metabolomics provide new platforms for high-throughput, highly sensitive, functional assays, biomarker discovery and offer opportunities for personalised medicine, complementing existing and emerging genomic, proteomic and transcriptomic technologies (<xref ref-type="fig" rid="f0020">Fig. 4</xref>). However, personalised medicine in the future could be better served when these biomarkers provide enough knowledge to translate them successfully into one or more types of wearable technologies that are readily available to an end user (as also illustrated in <xref ref-type="fig" rid="f0020">Fig. 4</xref>). Biosensors used in wearable technologies like smartphones <xref ref-type="bibr" rid="bib51">[51]</xref>, <xref ref-type="bibr" rid="bib52">[52]</xref>, smart-watches <xref ref-type="bibr" rid="bib53">[53]</xref> for monitoring heart conditions, health bands, necklaces, glucose monitoring contact lenses <xref ref-type="bibr" rid="bib54">[54]</xref>, <xref ref-type="bibr" rid="bib55">[55]</xref>, headbands <italic>etc.,</italic> are excellent innovations transferring biomarker discovery onto a more individual level. Technological advances translating biochemical changes into physical signals is not something new, but in this age of bionics and biohacking <xref ref-type="bibr" rid="bib56">[56]</xref>, it is putting the technology in the hands of end user and thus able to boost the personalised medicine movement <xref ref-type="bibr" rid="bib57">[57]</xref>. Although, we recognise that these devices should always be with continued consultation with a clinical practitioner who can advise the wearer; much like home testing for blood pressure is currently practiced.<fig id="f0020"><label>Fig. 4</label><caption><p>The future cycle of metabolomics precision medicine-based research and healthcare where academia, industrial partners, corporate data analytics work with patients’ wearable data collection devices to provide health monitoring solutions.</p></caption><alt-text id="at0020">Fig. 4</alt-text><graphic xlink:href="gr4"></graphic></fig></p>
<p>Metabolomics studies seldom lack information about the studied bio-system, and although this science is described as data rich, as many metabolites are measured, it often lacks a sizable population. Being able to translate a subset of metabolite measurements onto a set of devices that not only validates the results but also provides other useful complementary information about the patient we believe is the next step forward.</p>
<p>Chemometric-based analyses following any metabolomics study can immensely benefit from such wealth of continual metabolite data and metadata obtained from a target cohort. When metabolomics for the masses does occur the data processing may need to depend on large computing power and data storage space and these could be stored securely and privately within an advanced cloud-computing environment <xref ref-type="bibr" rid="bib58">[58]</xref>. In such a scenario, these measurements from different populations could be linked within the internet (so called internet of things (IoT)) allowing ensemble computation and for example epidemiological assessment of disease progression and spread (<xref ref-type="fig" rid="f0020">Fig. 4</xref>). This is not novel as the added benefit of current wearable biosensors is that the collected data are directly synced onto intelligent cloud services like Microsoft Azure or Google Cloud <xref ref-type="bibr" rid="bib59">[59]</xref>. An individuals (health) data collected over time <italic>via</italic> portable (a set of wearables) devices has the potential of producing copious amounts of telemetry data that can be computed over the cloud, producing predictions for <italic>future</italic> health risks. For example the mPower, mobile Parkinson's Disease (PD) study that attempts to research the occurrence, presentation and management of PD symptoms <italic>via</italic> survey telemetry data using a smartphone app <xref ref-type="bibr" rid="bib60">[60]</xref>. Another nice example is a smart-phone based application to monitor the association between pain and the weather for people suffering from rheumatoid arthritis <xref ref-type="bibr" rid="bib61">[61]</xref>. Use of artificial intelligence (AI) for screening, decision making and management whilest not new, can be adapted for risk stratification, prevention and choice of treatment in the healthcare systems <xref ref-type="bibr" rid="bib62">[62]</xref>. Recently, US Food and Drug Administration (FDA) has approved an AI based machine learning application for the use in clinics for making informed decisions about the health of heart where AI provides accurate measurements of the volume of each ventricle to physicians. This is thought to speed up and improve the decision making for heart surgeries <xref ref-type="bibr" rid="bib63">[63]</xref>. There is an enormous potential for a happy marriage between metabolomics and AI or machine learning technologies that are driven by data. This is where metabolomics should aim to take personalised medicine to - not only being able to predict a persons current or near future health or globally screen for potential biomarkers - but to link that information to dynamic metadata from patients to predict further risks and disease prognosis (<xref ref-type="fig" rid="f0005">Fig. 1</xref>). This approach as opposed to evidence-based medicine (<xref ref-type="fig" rid="f0015">Fig. 3</xref>) will enable better health care outcomes instead of trial and error treatment regimes.</p>
<p>A potential future scenario illustrating precision medicine were together the patient and physician are at the centre of the diagnostics is shown in <xref ref-type="fig" rid="f0025">Fig. 5</xref>, once the hurdles of costs, barriers to patient inclusion and ease of use are overcome <xref ref-type="bibr" rid="bib64">[64]</xref>. On the right-hand side of this figure is the expected laboratory-based scenario where metabolomics data are a standalone set of information which may be frequently linked to other ‘omics data. These measurements are detailed and thus slow and usually reserved for the initial diagnostics often when disease is already apparent. This provides useful but limited retrospective information about a population. By contrast the left-hand side illustrates the role of self-testing at home which can occur much more frequently, and for some wearable devices constantly and in real-time. For example, using dipstick tests for diabetes may be a quicker assessment of glucose levels but as is already known by individuals with Type I diabetes lacks real-time prolonged monitoring of patient health. As mentioned above implantable devices are now available for real-time glucose sensing and when combined with a ‘health band’ which reports information on a patients sleep patterns, heart rate, and physical exercise schedules may lead to better management of the disease.<fig id="f0025"><label>Fig. 5</label><caption><p>A potential future where the patient is at the centre of their own health care. Where research/omics data and clinical data (right sides) are combined with novel future wearable and at home testing to generate more precise and thus precision medicine-based diagnostics. Thus, bucketing patients with similar health profiles would aid clinics to differentiate those that need urgent medical intervention from those that will benefit more from change in lifestyle choices and non-medical aid. This approach can thus help identify subgroup(s) of patients with similar drug responses or disease profiles, enabling affordable care as proposed by the Obama Care Bill without excluding those with pre-existing health conditions (that are not deemed life threatening but manageable) or comorbidities.</p></caption><alt-text id="at0025">Fig. 5</alt-text><graphic xlink:href="gr5"></graphic></fig></p>
</sec>
<sec id="s0030">
<label>6</label>
<title>Conclusions</title>
<p>The future of metabolomics does not stop at personalised medicine itself. For the application of metabolomics in preventive medicine as well as screening, the world is your oyster. Indeed, metabolomics could play not only a crucial role in monitoring life on the Earth but also beyond <xref ref-type="bibr" rid="bib65">[65]</xref>. NASA's recent famous twin study which was concluded last year will hopefully show a glimpse of how powerful and useful understanding the human metabolome can be <xref ref-type="bibr" rid="bib66">[66]</xref>, <xref ref-type="bibr" rid="bib67">[67]</xref>.</p>
<p>At present metabolomics is very much research laboratory-based and needs to move out of academic laboratories and into the clinic. As a step towards this the UK has established two Phenome centres <xref ref-type="bibr" rid="bib68">[68]</xref>, one in London and the other in Birmingham; time will tell whether these are successful but a real opportunity is presented for the large-scale use of metabolomics for preventive health care, disease diagnosis, disease monitoring as well as finding novel therapeutics on a personalised level, which will account for differences within each individual.</p>
<p>A recently published white paper demonstrates the strengths of metabolomics in shaping precision medicine <xref ref-type="bibr" rid="bib69">[69]</xref>, and we would urge all readers to dip into the text along with the accompanying Topical Issue published in <italic>Metabolomics</italic> on “Recent advances in Pharmacometabolomics: enabling tools for precision medicine” <xref ref-type="bibr" rid="bib70">[70]</xref>.</p>
<p>As the ancient proverb says:<disp-quote><p>“<italic>Vita brevis, ars longa, occasio praeceps, experimentum periculosum, iudicium difficile</italic>” <xref ref-type="bibr" rid="bib71">[71]</xref></p></disp-quote></p>
<p>which translates to:<disp-quote><p>“Life is short, and art long, opportunity fleeting, experimentations perilous, and judgement difficult.”</p></disp-quote></p>
<p>Thus, there is an urgent and somewhat imminent need for precision medicine! This will require appropriate infrastructure for <italic>metabolomics for (and indeed on) the masses</italic> and will require alterations in healthcare practices across the globe. Once delivered this may improve medicine, put the patient at the centre of the analysis, and allow for healthier lifestyles and efficient medication for each and every one of us.</p>
</sec>
</body>
<back>
<ref-list id="bibliog0005">
<title>References</title>
<ref id="bib1">
<label>1</label>
<element-citation id="sbref1" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Oliver</surname>
<given-names>S.G.</given-names>
</name>
</person-group>
<article-title>Systematic functional analysis of the yeast genome</article-title>
<source/>Trends Biotechnol.
          <volume>16</volume>
<issue>9</issue>
<year>1998</year>
<fpage>373</fpage>
<lpage>378</lpage>
<pub-id pub-id-type="pmid">9744112</pub-id>
</element-citation>
</ref>
<ref id="bib2">
<label>2</label>
<element-citation id="sbref2" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kell</surname>
<given-names>D.B.</given-names>
</name>
<name>
<surname>Oliver</surname>
<given-names>S.G.</given-names>
</name>
</person-group>
<article-title>The metabolome 18 years on: a concept comes of age</article-title>
<source/>Metabolomics
          <volume>12</volume>
<issue>9</issue>
<year>2016</year>
<fpage>148</fpage>
<pub-id pub-id-type="pmid">27695392</pub-id>
</element-citation>
</ref>
<ref id="bib3">
<label>3</label>
<element-citation id="sbref3" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Strimbu</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Tavel</surname>
<given-names>J.A.</given-names>
</name>
</person-group>
<article-title>What are biomarkers?</article-title>
<source/>Curr. Opin. HIV AIDS
          <volume>5</volume>
<issue>6</issue>
<year>2010</year>
<fpage>463</fpage>
<lpage>466</lpage>
<pub-id pub-id-type="pmid">20978388</pub-id>
</element-citation>
</ref>
<ref id="bib4">
<label>4</label>
<element-citation id="sbref4" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Broadhurst</surname>
<given-names>D.I.</given-names>
</name>
<name>
<surname>Kell</surname>
<given-names>D.B.</given-names>
</name>
</person-group>
<article-title>Statistical strategies for avoiding false discoveries in metabolomics and related experiments</article-title>
<source/>Metabolomics
          <volume>2</volume>
<issue>4</issue>
<year>2006</year>
<fpage>171</fpage>
<lpage>196</lpage>
</element-citation>
</ref>
<ref id="bib5">
<label>5</label>
<element-citation id="sbref5" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Poste</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>Bring on the biomarkers</article-title>
<source/>Nature
          <volume>469</volume>
<issue>7329</issue>
<year>2011</year>
<fpage>156</fpage>
<lpage>157</lpage>
<pub-id pub-id-type="pmid">21228852</pub-id>
</element-citation>
</ref>
<ref id="bib6">
<label>6</label>
<mixed-citation id="othref0005" publication-type="other">Nix, H., A National Geographic Information System - An Achievable Objective?, in: Keynote address, Aurisa, 1990.</mixed-citation>
</ref>
<ref id="bib7">
<label>7</label>
<element-citation id="sbref6" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sansone</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Goodacre</surname>
<given-names>F.T.</given-names>
</name>
<name>
<surname>Griffin</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Wardy</surname>
<given-names>J.L.</given-names>
</name>
<name>
<surname>Kaddurah-Daouk</surname>
<given-names>N.W.</given-names>
</name>
<name>
<surname>Kristal</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>London</surname>
<given-names>B.S.</given-names>
</name>
<name>
<surname>Mendes</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Morrison</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Nikolau</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Robertson</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Sumner</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Taylor</surname>
<given-names>L.W.</given-names>
</name>
<name>
<surname>van der Werf</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Ommen</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Fiehn O</surname>
<given-names>B.V.</given-names>
</name>
</person-group>
<article-title>The metabolomics standards initiative</article-title>
<source/>Nat. Biotechnol.
          <volume>25</volume>
<issue>8</issue>
<year>2007</year>
<fpage>846</fpage>
<lpage>848</lpage>
<pub-id pub-id-type="pmid">17687353</pub-id>
</element-citation>
</ref>
<ref id="bib8">
<label>8</label>
<element-citation id="sbref7" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Statistics</surname>
<given-names>Of.N.</given-names>
</name>
</person-group>
<article-title>Registered deaths by age, sex, selected underlying causes of death, and the 10 leading causes of death for both males and females</article-title>
<source/>Stat. Bull.
          <year>2015</year>
</element-citation>
</ref>
<ref id="bib9">
<label>9</label>
<element-citation id="sbref8" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Commission</surname>
<given-names>E.</given-names>
</name>
</person-group>
<article-title>Causes of death - standardised death rate by residence</article-title>
<source/>Eurostat
          <year>2013</year>
</element-citation>
</ref>
<ref id="bib10">
<label>10</label>
<element-citation id="sbref9" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>O’Neill</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Review on antimicrobial resistance</article-title>
<source/>Antimicrob. Resist.: Tackling Crisis Health Wealth Nations
          <year>2014</year>
</element-citation>
</ref>
<ref id="bib11">
<label>11</label>
<element-citation id="sbref10" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Goodacre</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>Metabolomics of a superorganism</article-title>
<source/>J. Nutr.
          <volume>137</volume>
<issue>1</issue>
<year>2007</year>
<fpage>259S</fpage>
<lpage>266S</lpage>
<pub-id pub-id-type="pmid">17182837</pub-id>
</element-citation>
</ref>
<ref id="bib12">
<label>12</label>
<element-citation id="sbref11" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Potgieter</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>The dormant blood microbiome in chronic, inflammatory diseases</article-title>
<source/>FEMS Microbiol. Rev.
          <volume>39</volume>
<issue>4</issue>
<year>2015</year>
<fpage>567</fpage>
<lpage>591</lpage>
<pub-id pub-id-type="pmid">25940667</pub-id>
</element-citation>
</ref>
<ref id="bib13">
<label>13</label>
<element-citation id="sbref12" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kaufman</surname>
<given-names>D.J.</given-names>
</name>
</person-group>
<article-title>A survey of US adults' opinions about conduct of a nationwide precision medicine Initiative® cohort study of genes and environment</article-title>
<source/>PLoS One
          <volume>11</volume>
<issue>8</issue>
<year>2016</year>
<fpage>e0160461</fpage>
<pub-id pub-id-type="pmid">27532667</pub-id>
</element-citation>
</ref>
<ref id="bib14">
<label>14</label>
<mixed-citation id="othref0010" publication-type="other">N.O.O. Communications, NIH funds biobank to support Precision Medicine Initiative Cohort Program, in: NIH News Releases, 2016. [online].</mixed-citation>
</ref>
<ref id="bib15">
<label>15</label>
<mixed-citation id="othref0015" publication-type="other">FDA, Precision Medicine. Science and Research Special Topics, 2016.</mixed-citation>
</ref>
<ref id="bib16">
<label>16</label>
<element-citation id="sbref13" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Beger</surname>
<given-names>R.D.</given-names>
</name>
</person-group>
<article-title>Metabolomics enables precision medicine: “a white paper, community perspective”</article-title>
<source/>Metabolomics
          <volume>12</volume>
<issue>9</issue>
<year>2016</year>
<fpage>149</fpage>
<pub-id pub-id-type="pmid">27642271</pub-id>
</element-citation>
</ref>
<ref id="bib17">
<label>17</label>
<element-citation id="sbref14" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Neavin</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Kaddurah-Daouk</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Weinshilboum</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>Pharmacometabolomics informs pharmacogenomics</article-title>
<source/>Metabolomics
          <volume>12</volume>
<year>2016</year>
<fpage>7</fpage>
</element-citation>
</ref>
<ref id="bib18">
<label>18</label>
<element-citation id="sbref15" publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Crockett</surname>
<given-names>D.</given-names>
</name>
</person-group>
<person-group person-group-type="editor">
<name>
<surname>Crockett</surname>
<given-names>D.</given-names>
</name>
</person-group>
<source/>Going Beyond Genomics in Precision Medicine: What's Next
          <year>2016</year>
<publisher-name>Healthcare Transformation and Precision Medicine</publisher-name>
<ext-link ext-link-type="uri" id="ir0015" xlink:href="https://www.healthcatalyst.com">https://www.healthcatalyst.com</ext-link>
</element-citation>
</ref>
<ref id="bib19">
<label>19</label>
<element-citation id="sbref16" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Clish</surname>
<given-names>C.B.</given-names>
</name>
</person-group>
<article-title>Metabolomics: an emerging but powerful tool for precision medicine</article-title>
<source/>Mol. Case Stud.
          <volume>1</volume>
<issue>1</issue>
<year>2015</year>
</element-citation>
</ref>
<ref id="bib20">
<label>20</label>
<element-citation id="sbref17" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Monteiro</surname>
<given-names>M.S.</given-names>
</name>
</person-group>
<article-title>Metabolomics analysis for biomarker discovery: advances and challenges</article-title>
<source/>Curr. Med. Chem.
          <volume>20</volume>
<issue>2</issue>
<year>2013</year>
<fpage>257</fpage>
<lpage>271</lpage>
<pub-id pub-id-type="pmid">23210853</pub-id>
</element-citation>
</ref>
<ref id="bib21">
<label>21</label>
<element-citation id="sbref18" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Armitage</surname>
<given-names>E.G.</given-names>
</name>
<name>
<surname>Barbas</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>Metabolomics in cancer biomarker discovery: current trends and future perspectives</article-title>
<source/>J. Pharm. Biomed. Anal.
          <volume>87</volume>
<year>2014</year>
<fpage>1</fpage>
<lpage>11</lpage>
<pub-id pub-id-type="pmid">24091079</pub-id>
</element-citation>
</ref>
<ref id="bib22">
<label>22</label>
<element-citation id="sbref19" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kell</surname>
<given-names>D.B.</given-names>
</name>
</person-group>
<article-title>Metabolomic biomarkers: search, discovery and validation</article-title>
<source/>Expert Rev. Mol. Diagn.
          <volume>7</volume>
<issue>4</issue>
<year>2007</year>
<fpage>329</fpage>
<lpage>333</lpage>
<pub-id pub-id-type="pmid">17620040</pub-id>
</element-citation>
</ref>
<ref id="bib23">
<label>23</label>
<element-citation id="sbref20" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Altadill</surname>
<given-names>T.</given-names>
</name>
</person-group>
<article-title>Enabling metabolomics based biomarker discovery studies using molecular phenotyping of exosome-like vesicles</article-title>
<source/>PLoS One
          <volume>11</volume>
<issue>3</issue>
<year>2016</year>
<fpage>e0151339</fpage>
<pub-id pub-id-type="pmid">26974972</pub-id>
</element-citation>
</ref>
<ref id="bib24">
<label>24</label>
<element-citation id="sbref21" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xia</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Translational biomarker discovery in clinical metabolomics: an introductory tutorial</article-title>
<source/>Metabolomics
          <volume>9</volume>
<issue>2</issue>
<year>2013</year>
<fpage>280</fpage>
<lpage>299</lpage>
<pub-id pub-id-type="pmid">23543913</pub-id>
</element-citation>
</ref>
<ref id="bib25">
<label>25</label>
<element-citation id="sbref22" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dhanasekaran</surname>
<given-names>S.M.</given-names>
</name>
</person-group>
<article-title>Delineation of prognostic biomarkers in prostate cancer</article-title>
<source/>Nature
          <volume>412</volume>
<issue>6849</issue>
<year>2001</year>
<fpage>822</fpage>
<lpage>826</lpage>
<pub-id pub-id-type="pmid">11518967</pub-id>
</element-citation>
</ref>
<ref id="bib26">
<label>26</label>
<element-citation id="sbref23" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pashayan</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Pharoah</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>Population-based screening in the era of genomics</article-title>
<source/>Personal. Med.
          <volume>9</volume>
<issue>4</issue>
<year>2012</year>
<fpage>451</fpage>
<lpage>455</lpage>
</element-citation>
</ref>
<ref id="bib27">
<label>27</label>
<element-citation id="sbref24" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Guo</surname>
<given-names>L.</given-names>
</name>
</person-group>
<article-title>Plasma metabolomic profiles enhance precision medicine for volunteers of normal health</article-title>
<source/>Proc. Natl. Acad. Sci. USA
          <volume>112</volume>
<issue>35</issue>
<year>2015</year>
<fpage>E4901</fpage>
<lpage>E4910</lpage>
<pub-id pub-id-type="pmid">26283345</pub-id>
</element-citation>
</ref>
<ref id="bib28">
<label>28</label>
<element-citation id="sbref25" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vanmassenhove</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Urinary and serum biomarkers for the diagnosis of acute kidney injury: an in-depth review of the literature</article-title>
<source/>Nephrol. Dial. Transplant.
          <volume>28</volume>
<issue>2</issue>
<year>2013</year>
<fpage>254</fpage>
<lpage>273</lpage>
<pub-id pub-id-type="pmid">23115326</pub-id>
</element-citation>
</ref>
<ref id="bib29">
<label>29</label>
<element-citation id="sbref26" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mathelin</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>Serum biomarkers for detection of breast cancers: a prospective study</article-title>
<source/>Breast Cancer Res. Treat.
          <volume>96</volume>
<issue>1</issue>
<year>2006</year>
<fpage>83</fpage>
<lpage>90</lpage>
<pub-id pub-id-type="pmid">16322896</pub-id>
</element-citation>
</ref>
<ref id="bib30">
<label>30</label>
<element-citation id="sbref27" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tessitore</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Serum biomarkers identification by mass spectrometry in high-mortality tumors</article-title>
<source/>Int. J. Proteom.
          <volume>2013</volume>
<year>2013</year>
<fpage>15</fpage>
</element-citation>
</ref>
<ref id="bib31">
<label>31</label>
<element-citation id="sbref28" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chung</surname>
<given-names>L.</given-names>
</name>
</person-group>
<article-title>Novel serum protein biomarker panel revealed by mass spectrometry and its prognostic value in breast cancer</article-title>
<source/>Breast Cancer Res.
          <volume>16</volume>
<issue>3</issue>
<year>2014</year>
<fpage>R63</fpage>
<pub-id pub-id-type="pmid">24935269</pub-id>
</element-citation>
</ref>
<ref id="bib32">
<label>32</label>
<element-citation id="sbref29" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shen</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>Developing urinary metabolomic signatures as early bladder cancer diagnostic markers</article-title>
<source/>Omics
          <volume>19</volume>
<issue>1</issue>
<year>2015</year>
<fpage>1</fpage>
<lpage>11</lpage>
<pub-id pub-id-type="pmid">25562196</pub-id>
</element-citation>
</ref>
<ref id="bib33">
<label>33</label>
<element-citation id="sbref30" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kim</surname>
<given-names>K.</given-names>
</name>
</person-group>
<article-title>Urine metabolomic analysis identifies potential biomarkers and pathogenic pathways in kidney cancer</article-title>
<source/>OMICS: J. Integr. Biol.
          <volume>15</volume>
<issue>5</issue>
<year>2011</year>
<fpage>293</fpage>
<lpage>303</lpage>
</element-citation>
</ref>
<ref id="bib34">
<label>34</label>
<element-citation id="sbref31" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Trivedi</surname>
<given-names>D.K.</given-names>
</name>
<name>
<surname>Iles</surname>
<given-names>R.K.</given-names>
</name>
</person-group>
<article-title>Shotgun metabolomic profiles in maternal urine identify potential mass spectral markers of abnormal fetal biochemistry - dihydrouracil and progesterone in the metabolism of Down syndrome</article-title>
<source/>Biomed. Chromatogr.
          <volume>29</volume>
<issue>8</issue>
<year>2015</year>
<fpage>1173</fpage>
<lpage>1183</lpage>
<pub-id pub-id-type="pmid">25545476</pub-id>
</element-citation>
</ref>
<ref id="bib35">
<label>35</label>
<element-citation id="sbref32" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Laiakis</surname>
<given-names>E.C.</given-names>
</name>
</person-group>
<article-title>Metabolomic analysis in severe childhood pneumonia in The Gambia, West Africa: findings from a pilot study</article-title>
<source/>PLoS One
          <volume>5</volume>
<issue>9</issue>
<year>2010</year>
<fpage>e12655</fpage>
<pub-id pub-id-type="pmid">20844590</pub-id>
</element-citation>
</ref>
<ref id="bib36">
<label>36</label>
<element-citation id="sbref33" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>van de Kant</surname>
<given-names>K.D.G.</given-names>
</name>
</person-group>
<article-title>Clinical use of exhaled volatile organic compounds in pulmonary diseases: a systematic review</article-title>
<source/>Respir. Res.
          <volume>13</volume>
<issue>1</issue>
<year>2012</year>
<comment>(117-117)</comment>
</element-citation>
</ref>
<ref id="bib37">
<label>37</label>
<mixed-citation id="othref0020" publication-type="other">R. Schnabel, et al., Analysis of volatile organic compounds in exhaled breath to diagnose ventilator-associated pneumonia. Scientific Reports. 5, 2015, p. 17179.</mixed-citation>
</ref>
<ref id="bib38">
<label>38</label>
<element-citation id="sbref34" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sethi</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Nanda</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Chakraborty</surname>
<given-names>T.</given-names>
</name>
</person-group>
<article-title>Clinical application of volatile organic compound analysis for detecting infectious diseases</article-title>
<source/>Clin. Microbiol. Rev.
          <volume>26</volume>
<issue>3</issue>
<year>2013</year>
<fpage>462</fpage>
<lpage>475</lpage>
<pub-id pub-id-type="pmid">23824368</pub-id>
</element-citation>
</ref>
<ref id="bib39">
<label>39</label>
<element-citation id="sbref35" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hollywood</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Brison</surname>
<given-names>D.R.</given-names>
</name>
<name>
<surname>Goodacre</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>Metabolomics: current technologies and future trends</article-title>
<source/>Proteomics
          <volume>6</volume>
<issue>17</issue>
<year>2006</year>
<fpage>4716</fpage>
<lpage>4723</lpage>
<pub-id pub-id-type="pmid">16888765</pub-id>
</element-citation>
</ref>
<ref id="bib40">
<label>40</label>
<element-citation id="sbref36" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dunn</surname>
<given-names>W.B.</given-names>
</name>
</person-group>
<article-title>Molecular phenotyping of a UK population: defining the human serum metabolome</article-title>
<source/>Metabolomics
          <volume>11</volume>
<year>2015</year>
<fpage>9</fpage>
<lpage>26</lpage>
<pub-id pub-id-type="pmid">25598764</pub-id>
</element-citation>
</ref>
<ref id="bib41">
<label>41</label>
<element-citation id="sbref37" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ganna</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Large-scale metabolomic profiling identifies novel biomarkers for incident coronary heart disease</article-title>
<source/>PLoS Genet.
          <volume>10</volume>
<issue>12</issue>
<year>2014</year>
<fpage>e1004801</fpage>
<pub-id pub-id-type="pmid">25502724</pub-id>
</element-citation>
</ref>
<ref id="bib42">
<label>42</label>
<element-citation id="sbref38" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Albright</surname>
<given-names>J.C.</given-names>
</name>
</person-group>
<article-title>Large-scale metabolomics reveals a complex response of aspergillus nidulans to epigenetic perturbation</article-title>
<source/>ACS Chem. Biol.
          <volume>10</volume>
<issue>6</issue>
<year>2015</year>
<fpage>1535</fpage>
<lpage>1541</lpage>
<pub-id pub-id-type="pmid">25815712</pub-id>
</element-citation>
</ref>
<ref id="bib43">
<label>43</label>
<element-citation id="sbref39" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Harris</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>Overview of screening: where we are and where we may be headed</article-title>
<source/>Epidemiol. Rev.
          <volume>33</volume>
<issue>1</issue>
<year>2011</year>
<fpage>1</fpage>
<lpage>6</lpage>
<pub-id pub-id-type="pmid">21709142</pub-id>
</element-citation>
</ref>
<ref id="bib44">
<label>44</label>
<element-citation id="sbref40" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Khoury</surname>
<given-names>M.J.</given-names>
</name>
<name>
<surname>McCabe</surname>
<given-names>L.L.</given-names>
</name>
<name>
<surname>McCabe</surname>
<given-names>E.R.B.</given-names>
</name>
</person-group>
<article-title>Population screening in the age of genomic medicine</article-title>
<source/>N. Engl. J. Med.
          <volume>348</volume>
<issue>1</issue>
<year>2003</year>
<fpage>50</fpage>
<lpage>58</lpage>
<pub-id pub-id-type="pmid">12510043</pub-id>
</element-citation>
</ref>
<ref id="bib45">
<label>45</label>
<element-citation id="sbref41" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Munafò</surname>
<given-names>M.R.</given-names>
</name>
</person-group>
<article-title>A manifesto for reproducible science</article-title>
<source/>Nat. Hum. Behav.
          <volume>1</volume>
<year>2017</year>
<fpage>0021</fpage>
</element-citation>
</ref>
<ref id="bib46">
<label>46</label>
<element-citation id="sbref42" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dunn</surname>
<given-names>W.B.</given-names>
</name>
</person-group>
<article-title>The importance of experimental design and QC samples in large-scale and MS-driven untargeted metabolomic studies of humans</article-title>
<source/>Bioanalysis
          <volume>4</volume>
<issue>18</issue>
<year>2012</year>
<fpage>2249</fpage>
<lpage>2264</lpage>
<pub-id pub-id-type="pmid">23046267</pub-id>
</element-citation>
</ref>
<ref id="bib47">
<label>47</label>
<element-citation id="sbref43" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wen</surname>
<given-names>H.</given-names>
</name>
</person-group>
<article-title>A new NMR-based metabolomics approach for the diagnosis of biliary tract cancer</article-title>
<source/>J. Hepatol.
          <volume>52</volume>
<issue>2</issue>
<year>2010</year>
<fpage>228</fpage>
<lpage>233</lpage>
<pub-id pub-id-type="pmid">20036026</pub-id>
</element-citation>
</ref>
<ref id="bib48">
<label>48</label>
<element-citation id="sbref44" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Costa e Silva</surname>
<given-names>J.A.</given-names>
</name>
</person-group>
<article-title>Personalized medicine in psychiatry: new technologies and approaches</article-title>
<source/>Metabolism
          <volume>62</volume>
<issue>Suppl. 1</issue>
<year>2013</year>
<fpage>S40</fpage>
<lpage>S44</lpage>
<pub-id pub-id-type="pmid">23018148</pub-id>
</element-citation>
</ref>
<ref id="bib49">
<label>49</label>
<mixed-citation id="othref0025" publication-type="other">Harrer, S. Measuring Life: Sensors and Analytics for Precision Medicine, 2015.</mixed-citation>
</ref>
<ref id="bib50">
<label>50</label>
<element-citation id="sbref45" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vaddiraju</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Technologies for Continuous Glucose Monitoring: current Problems and Future Promises</article-title>
<source/>J. Diabetes Sci. Technol.
          <volume>4</volume>
<issue>6</issue>
<year>2010</year>
<fpage>1540</fpage>
<lpage>1562</lpage>
<pub-id pub-id-type="pmid">21129353</pub-id>
</element-citation>
</ref>
<ref id="bib51">
<label>51</label>
<element-citation id="sbref46" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>BinDhim</surname>
<given-names>N.F.</given-names>
</name>
</person-group>
<article-title>Depression screening via a smartphone app: cross-country user characteristics and feasibility</article-title>
<source/>J. Am. Med. Inform. Assoc.
          <volume>22</volume>
<issue>1</issue>
<year>2015</year>
<fpage>29</fpage>
<lpage>34</lpage>
<pub-id pub-id-type="pmid">25326599</pub-id>
</element-citation>
</ref>
<ref id="bib52">
<label>52</label>
<element-citation id="sbref47" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nam</surname>
<given-names>H.S.</given-names>
</name>
</person-group>
<article-title>Development of smartphone application that aids stroke screening and identifying nearby acute stroke care hospitals</article-title>
<source/>Yonsei Med. J.
          <volume>55</volume>
<issue>1</issue>
<year>2014</year>
<fpage>25</fpage>
<lpage>29</lpage>
<pub-id pub-id-type="pmid">24339283</pub-id>
</element-citation>
</ref>
<ref id="bib53">
<label>53</label>
<mixed-citation id="othref0030" publication-type="other">C. Boletsis, S. McCallum, B.F. Landmark, The use of smartwatches for health monitoring in home-based dementia care, in: Human Aspects of IT for the Aged Population. Design for Everyday Life: First International Conference, ITAP 2015, Held as Part of HCI International 2015, Los Angeles, CA, USA, August 2–7, 2015. Proceedings, Part II, J. Zhou and G. Salvendy, Editors, Cham, Springer International Publishing, 2015, pp. 15–26.</mixed-citation>
</ref>
<ref id="bib54">
<label>54</label>
<element-citation id="sbref48" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Badugu</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Lakowicz</surname>
<given-names>J.R.</given-names>
</name>
<name>
<surname>Geddes</surname>
<given-names>C.D.</given-names>
</name>
</person-group>
<article-title>A glucose-sensing contact lens: from bench top to patient</article-title>
<source/>Curr. Opin. Biotechnol.
          <volume>16</volume>
<issue>1</issue>
<year>2005</year>
<fpage>100</fpage>
<lpage>107</lpage>
<pub-id pub-id-type="pmid">15722022</pub-id>
</element-citation>
</ref>
<ref id="bib55">
<label>55</label>
<element-citation id="sbref49" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chu</surname>
<given-names>M.X.</given-names>
</name>
</person-group>
<article-title>Soft contact lens biosensor for in situ monitoring of tear glucose as non-invasive blood sugar assessment</article-title>
<source/>Talanta
          <volume>83</volume>
<issue>3</issue>
<year>2011</year>
<fpage>960</fpage>
<lpage>965</lpage>
<pub-id pub-id-type="pmid">21147344</pub-id>
</element-citation>
</ref>
<ref id="bib56">
<label>56</label>
<element-citation id="sbref50" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bodhani</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>The connected body</article-title>
<source/>Eng. Technol.
          <volume>10</volume>
<issue>4</issue>
<year>2015</year>
<fpage>44</fpage>
<lpage>47</lpage>
</element-citation>
</ref>
<ref id="bib57">
<label>57</label>
<element-citation id="sbref51" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Marschollek</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Wearable sensors in healthcare and sensor-enhanced health information systems: all our tomorrows?</article-title>
<source/>Healthc. Inform. Res.
          <volume>18</volume>
<issue>2</issue>
<year>2012</year>
<fpage>97</fpage>
<lpage>104</lpage>
<pub-id pub-id-type="pmid">22844645</pub-id>
</element-citation>
</ref>
<ref id="bib58">
<label>58</label>
<element-citation id="sbref52" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sarkar</surname>
<given-names>B.K.</given-names>
</name>
</person-group>
<article-title>Big data for secure healthcare system: a conceptual design</article-title>
<source/>Complex Intell. Syst.
          <year>2017</year>
<fpage>1</fpage>
<lpage>19</lpage>
</element-citation>
</ref>
<ref id="bib59">
<label>59</label>
<element-citation id="sbref53" publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Park</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Chung</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Jayaraman</surname>
<given-names>S.</given-names>
</name>
</person-group>
<chapter-title>1 - wearables: fundamentals, advancements, and a roadmap for the future A2 - Sazonov, Edward</chapter-title>
<person-group person-group-type="editor">
<name>
<surname>Neuman</surname>
<given-names>M.R.</given-names>
</name>
</person-group>
<source/>Wearable Sensors
          <edition>Chapter 1</edition>
<year>2014</year>
<publisher-name>Academic Press</publisher-name>
<publisher-loc>Oxford</publisher-loc>
<fpage>1</fpage>
<lpage>23</lpage>
</element-citation>
</ref>
<ref id="bib60">
<label>60</label>
<element-citation id="sbref54" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bot</surname>
<given-names>B.M.</given-names>
</name>
</person-group>
<article-title>The mPower study, Parkinson disease mobile data collected using Research Kit</article-title>
<source/>Sci. Data
          <volume>3</volume>
<year>2016</year>
<fpage>160011</fpage>
<pub-id pub-id-type="pmid">26938265</pub-id>
</element-citation>
</ref>
<ref id="bib61">
<label>61</label>
<element-citation id="sbref55" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Reade</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Cloudy with a chance of pain: engagement and subsequent attrition of daily data entry in a smartphone pilot study tracking weather, disease severity, and physical activity in patients with rheumatoid arthritis</article-title>
<source/>JMIR Mhealth Uhealth
          <volume>5</volume>
<issue>3</issue>
<year>2017</year>
<fpage>e37</fpage>
<pub-id pub-id-type="pmid">28341616</pub-id>
</element-citation>
</ref>
<ref id="bib62">
<label>62</label>
<element-citation id="sbref56" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Long</surname>
<given-names>E.</given-names>
</name>
</person-group>
<article-title>An artificial intelligence platform for the multihospital collaborative management of congenital cataracts</article-title>
<source/>Nat. Biomed. Eng.
          <volume>1</volume>
<year>2017</year>
<fpage>0024</fpage>
</element-citation>
</ref>
<ref id="bib63">
<label>63</label>
<element-citation id="sbref57" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Marr</surname>
<given-names>B.</given-names>
</name>
</person-group>
<article-title>First FDA approval for clinical cloud-based deep learning in healthcare</article-title>
<source/>Forbes
          <year>2017</year>
<comment>(online)</comment>
</element-citation>
</ref>
<ref id="bib64">
<label>64</label>
<element-citation id="sbref58" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bonham</surname>
<given-names>V.L.</given-names>
</name>
<name>
<surname>Callier</surname>
<given-names>S.L.</given-names>
</name>
<name>
<surname>Royal</surname>
<given-names>C.D.</given-names>
</name>
</person-group>
<article-title>Will precision medicine move us beyond race?</article-title>
<source/>N. Engl. J. Med.
          <volume>374</volume>
<issue>21</issue>
<year>2016</year>
<fpage>2003</fpage>
<lpage>2005</lpage>
<pub-id pub-id-type="pmid">27223144</pub-id>
</element-citation>
</ref>
<ref id="bib65">
<label>65</label>
<element-citation id="sbref59" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schmidt</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>Goodwin</surname>
<given-names>T.J.</given-names>
</name>
</person-group>
<article-title>Personalized medicine in human space flight: using Omics based analyses to develop individualized countermeasures that enhance astronaut safety and performance</article-title>
<source/>Metabolomics
          <volume>9</volume>
<issue>6</issue>
<year>2013</year>
<fpage>1134</fpage>
<lpage>1156</lpage>
<pub-id pub-id-type="pmid">24273472</pub-id>
</element-citation>
</ref>
<ref id="bib66">
<label>66</label>
<mixed-citation id="othref0035" publication-type="other">NASA, Metabolomic and Genomic Markers of Atherosclerosis as Related to Oxidative Stress, Inflammation, and Vascular Function in Twin Astronauts. ISS Science for Everyone, 2016.</mixed-citation>
</ref>
<ref id="bib67">
<label>67</label>
<mixed-citation id="othref0040" publication-type="other">NASA, Human Exploration Research Opportunities - Differential Effects on Homozygous Twin Astronauts Associated with Differences in Exposure to Spaceflight Factors ISS Science for Everyone, 2016.</mixed-citation>
</ref>
<ref id="bib68">
<label>68</label>
<element-citation id="sbref60" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lindon</surname>
<given-names>J.C.</given-names>
</name>
<name>
<surname>Nicholson</surname>
<given-names>J.K.</given-names>
</name>
</person-group>
<article-title>The emergent role of metabolic phenotyping in dynamic patient stratification</article-title>
<source/>Expert Opin. Drug Metab. Toxicol.
          <volume>10</volume>
<issue>7</issue>
<year>2014</year>
<fpage>915</fpage>
<lpage>919</lpage>
<pub-id pub-id-type="pmid">24905565</pub-id>
</element-citation>
</ref>
<ref id="bib69">
<label>69</label>
<element-citation id="sbref61" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Beger</surname>
<given-names>R.D.</given-names>
</name>
</person-group>
<article-title>Metabolomics enables precision medicine: “a white paper, community perspective”</article-title>
<source/>Metabolomics
          <volume>12</volume>
<issue>10</issue>
<year>2016</year>
<fpage>1</fpage>
<lpage>15</lpage>
</element-citation>
</ref>
<ref id="bib70">
<label>70</label>
<element-citation id="sbref62" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rattray</surname>
<given-names>N.J.W.</given-names>
</name>
<name>
<surname>Daouk</surname>
<given-names>R.K.</given-names>
</name>
</person-group>
<article-title>PharmacometabOlomics and Precision Medicine Special Issue Editorial</article-title>
<source/>Metabolomics
          <volume>13</volume>
<issue>5</issue>
<year>2017</year>
<fpage>59</fpage>
</element-citation>
</ref>
<ref id="bib71">
<label>71</label>
<mixed-citation id="othref0045" publication-type="other">Hippocrates, Aphorisms, in: The genuine works of Hippocrates: translated from the Greek with a preliminary discourse and annotations, London, Sydenham Society, 1849.</mixed-citation>
</ref>
<ref id="bib72">
<label>72</label>
<element-citation id="sbref63" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kenny</surname>
<given-names>L.C.</given-names>
</name>
</person-group>
<article-title>Novel biomarkers for pre-eclampsia detected using metabolomics and machine learning</article-title>
<source/>Metabolomics
          <volume>1</volume>
<issue>3</issue>
<year>2005</year>
<fpage>227</fpage>
</element-citation>
</ref>
<ref id="bib73">
<label>73</label>
<element-citation id="sbref64" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>High performance liquid chromatography-mass spectrometry for metabonomics: potential biomarkers for acute deterioration of liver function in chronic hepatitis B</article-title>
<source/>J. Proteome Res.
          <volume>5</volume>
<issue>3</issue>
<year>2006</year>
<fpage>554</fpage>
<lpage>561</lpage>
<pub-id pub-id-type="pmid">16512670</pub-id>
</element-citation>
</ref>
<ref id="bib74">
<label>74</label>
<element-citation id="sbref65" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Holmes</surname>
<given-names>E.</given-names>
</name>
</person-group>
<article-title>Metabolic profiling of CSF: evidence that early intervention may impact on disease progression and outcome in schizophrenia</article-title>
<source/>PLoS Med.
          <volume>3</volume>
<issue>8</issue>
<year>2006</year>
<fpage>e327</fpage>
<pub-id pub-id-type="pmid">16933966</pub-id>
</element-citation>
</ref>
<ref id="bib75">
<label>75</label>
<element-citation id="sbref66" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yi</surname>
<given-names>L.-Z.</given-names>
</name>
</person-group>
<article-title>Plasma fatty acid metabolic profiling and biomarkers of type 2 diabetes mellitus based on GC/MS and PLS-LDA</article-title>
<source/>FEBS Lett.
          <volume>580</volume>
<issue>30</issue>
<year>2006</year>
<fpage>6837</fpage>
<lpage>6845</lpage>
<pub-id pub-id-type="pmid">17141227</pub-id>
</element-citation>
</ref>
<ref id="bib76">
<label>76</label>
<element-citation id="sbref67" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yin</surname>
<given-names>P.Y.</given-names>
</name>
</person-group>
<article-title>Metabonomics study of intestinal fistulas based on ultraperformance liquid chromatography coupled with Q-TOF mass spectrometry (UPLC/Q-TOF MS)</article-title>
<source/>J. Proteome Res.
          <volume>5</volume>
<issue>9</issue>
<year>2006</year>
<fpage>2135</fpage>
<lpage>2143</lpage>
<pub-id pub-id-type="pmid">16944924</pub-id>
</element-citation>
</ref>
<ref id="bib77">
<label>77</label>
<element-citation id="sbref68" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kaddurah-Daouk</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>Metabolomic mapping of atypical antipsychotic effects in schizophrenia</article-title>
<source/>Mol. Psychiatry
          <volume>12</volume>
<issue>10</issue>
<year>2007</year>
<fpage>934</fpage>
<lpage>945</lpage>
<pub-id pub-id-type="pmid">17440431</pub-id>
</element-citation>
</ref>
<ref id="bib78">
<label>78</label>
<element-citation id="sbref69" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wikoff</surname>
<given-names>W.R.</given-names>
</name>
</person-group>
<article-title>Metabolomics identifies perturbations in human disorders of propionate metabolism</article-title>
<source/>Clin. Chem.
          <volume>53</volume>
<issue>12</issue>
<year>2007</year>
<fpage>2169</fpage>
<lpage>2176</lpage>
<pub-id pub-id-type="pmid">17951291</pub-id>
</element-citation>
</ref>
<ref id="bib79">
<label>79</label>
<element-citation id="sbref70" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bogdanov</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Metabolomic profiling to develop blood biomarkers for Parkinson's disease</article-title>
<source/>Brain
          <volume>131</volume>
<issue>2</issue>
<year>2008</year>
<fpage>389</fpage>
<lpage>396</lpage>
<pub-id pub-id-type="pmid">18222993</pub-id>
</element-citation>
</ref>
<ref id="bib80">
<label>80</label>
<element-citation id="sbref71" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Practical approach for the identification and isomer elucidation of biomarkers detected in a metabonomic study for the discovery of individuals at risk for diabetes by integrating the chromatographic and mass spectrometric information</article-title>
<source/>Anal. Chem.
          <volume>80</volume>
<issue>4</issue>
<year>2008</year>
<fpage>1280</fpage>
<lpage>1289</lpage>
<pub-id pub-id-type="pmid">18193893</pub-id>
</element-citation>
</ref>
<ref id="bib81">
<label>81</label>
<element-citation id="sbref72" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lawton</surname>
<given-names>K.A.</given-names>
</name>
</person-group>
<article-title>Analysis of the adult human plasma metabolome</article-title>
<source/>Pharmacogenomics
          <volume>9</volume>
<issue>4</issue>
<year>2008</year>
<fpage>383</fpage>
<lpage>397</lpage>
<pub-id pub-id-type="pmid">18384253</pub-id>
</element-citation>
</ref>
<ref id="bib82">
<label>82</label>
<element-citation id="sbref73" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yi</surname>
<given-names>L.Z.</given-names>
</name>
</person-group>
<article-title>Plasma fatty acid metabolic profile coupled with uncorrelated linear discriminant analysis to diagnose and biomarker screening of type 2 diabetes and type 2 diabetic coronary heart diseases</article-title>
<source/>Metabolomics
          <volume>4</volume>
<issue>1</issue>
<year>2008</year>
<fpage>30</fpage>
<lpage>38</lpage>
</element-citation>
</ref>
<ref id="bib83">
<label>83</label>
<element-citation id="sbref74" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Erb</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>Toward improved grading of malignancy in oligodendrogliomas using metabolomics</article-title>
<source/>Magn. Reson. Med.
          <volume>59</volume>
<issue>5</issue>
<year>2008</year>
<fpage>959</fpage>
<lpage>965</lpage>
<pub-id pub-id-type="pmid">18429037</pub-id>
</element-citation>
</ref>
<ref id="bib84">
<label>84</label>
<element-citation id="sbref75" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yin</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>Serum metabolic profiling of abnormal savda by liquid chromatography/mass spectrometry</article-title>
<source/>J. Chromatogr. B
          <volume>871</volume>
<issue>2</issue>
<year>2008</year>
<fpage>322</fpage>
<lpage>327</lpage>
</element-citation>
</ref>
<ref id="bib85">
<label>85</label>
<element-citation id="sbref76" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Seli</surname>
<given-names>E.</given-names>
</name>
</person-group>
<article-title>Noninvasive metabolomic profiling of embryo culture media using proton nuclear magnetic resonance correlates with reproductive potential of embryos in women undergoing in vitro fertilization</article-title>
<source/>Fertil. Steril.
          <volume>90</volume>
<issue>6</issue>
<year>2008</year>
<fpage>2183</fpage>
<lpage>2189</lpage>
<pub-id pub-id-type="pmid">18842260</pub-id>
</element-citation>
</ref>
<ref id="bib86">
<label>86</label>
<element-citation id="sbref77" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Qiu</surname>
<given-names>Y.</given-names>
</name>
</person-group>
<article-title>Multivariate classification analysis of metabolomic data for candidate biomarker discovery in type 2 diabetes mellitus</article-title>
<source/>Metabolomics
          <volume>4</volume>
<issue>4</issue>
<year>2008</year>
<fpage>337</fpage>
<lpage>346</lpage>
</element-citation>
</ref>
<ref id="bib87">
<label>87</label>
<element-citation id="sbref78" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chan</surname>
<given-names>E.C.Y.</given-names>
</name>
</person-group>
<article-title>Metabolic profiling of human colorectal cancer using high-resolution magic angle spinning nuclear magnetic resonance (HR-MAS NMR) spectroscopy and gas chromatography mass spectrometry (GC/MS)</article-title>
<source/>J. Proteome Res.
          <volume>8</volume>
<issue>1</issue>
<year>2009</year>
<fpage>352</fpage>
<lpage>361</lpage>
<pub-id pub-id-type="pmid">19063642</pub-id>
</element-citation>
</ref>
<ref id="bib88">
<label>88</label>
<element-citation id="sbref79" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zheng</surname>
<given-names>X.</given-names>
</name>
</person-group>
<article-title>Plasma fatty acids metabolic profiling analysis of coronary heart disease based on GC–MS and pattern recognition</article-title>
<source/>J. Pharm. Biomed. Anal.
          <volume>49</volume>
<issue>2</issue>
<year>2009</year>
<fpage>481</fpage>
<lpage>486</lpage>
<pub-id pub-id-type="pmid">19058943</pub-id>
</element-citation>
</ref>
<ref id="bib89">
<label>89</label>
<element-citation id="sbref80" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rudnick</surname>
<given-names>D.A.</given-names>
</name>
</person-group>
<article-title>Serum α-NH(2)-butyric acid may predict spontaneous survival in pediatric acute liver failure</article-title>
<source/>Pediatr. Transplant.
          <volume>13</volume>
<issue>2</issue>
<year>2009</year>
<fpage>223</fpage>
<lpage>230</lpage>
<pub-id pub-id-type="pmid">18643912</pub-id>
</element-citation>
</ref>
<ref id="bib90">
<label>90</label>
<element-citation id="sbref81" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vallejo</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Plasma fingerprinting with GC-MS in acute coronary syndrome</article-title>
<source/>Anal. Bioanal. Chem.
          <volume>394</volume>
<issue>6</issue>
<year>2009</year>
<fpage>1517</fpage>
<lpage>1524</lpage>
<pub-id pub-id-type="pmid">19172251</pub-id>
</element-citation>
</ref>
<ref id="bib91">
<label>91</label>
<element-citation id="sbref82" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ahmed</surname>
<given-names>S.S.</given-names>
</name>
</person-group>
<article-title>Metabolic profiling of Parkinson's disease: evidence of biomarker from gene expression analysis and rapid neural network detection</article-title>
<source/>J. Biomed. Sci.
          <volume>16</volume>
<issue>1</issue>
<year>2009</year>
<fpage>63</fpage>
<pub-id pub-id-type="pmid">19594911</pub-id>
</element-citation>
</ref>
<ref id="bib92">
<label>92</label>
<element-citation id="sbref83" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname>
<given-names>H.</given-names>
</name>
</person-group>
<article-title>Metabolomic profiling of human urine in hepatocellular carcinoma patients using gas chromatography/mass spectrometry</article-title>
<source/>Anal. Chim. Acta
          <volume>648</volume>
<issue>1</issue>
<year>2009</year>
<fpage>98</fpage>
<lpage>104</lpage>
<pub-id pub-id-type="pmid">19616694</pub-id>
</element-citation>
</ref>
<ref id="bib93">
<label>93</label>
<element-citation id="sbref84" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Metabonomics research of diabetic nephropathy and type 2 diabetes mellitus based on UPLC–oaTOF-MS system</article-title>
<source/>Anal. Chim. Acta
          <volume>650</volume>
<issue>1</issue>
<year>2009</year>
<fpage>16</fpage>
<lpage>22</lpage>
<pub-id pub-id-type="pmid">19720167</pub-id>
</element-citation>
</ref>
<ref id="bib94">
<label>94</label>
<element-citation id="sbref85" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ritchie</surname>
<given-names>S.A.</given-names>
</name>
</person-group>
<article-title>Reduced levels of hydroxylated, polyunsaturated ultra long-chain fatty acids in the serum of colorectal cancer patients: implications for early screening and detection</article-title>
<source/>BMC Med.
          <volume>8</volume>
<issue>1</issue>
<year>2010</year>
<fpage>13</fpage>
<pub-id pub-id-type="pmid">20156336</pub-id>
</element-citation>
</ref>
<ref id="bib95">
<label>95</label>
<element-citation id="sbref86" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sugimoto</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Capillary electrophoresis mass spectrometry-based saliva metabolomics identified oral, breast and pancreatic cancer-specific profiles</article-title>
<source/>Metabolomics
          <volume>6</volume>
<issue>1</issue>
<year>2010</year>
<fpage>78</fpage>
<lpage>95</lpage>
<pub-id pub-id-type="pmid">20300169</pub-id>
</element-citation>
</ref>
<ref id="bib96">
<label>96</label>
<element-citation id="sbref87" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lokhov</surname>
<given-names>P.G.</given-names>
</name>
</person-group>
<article-title>Metabolite profiling of blood plasma of patients with prostate cancer</article-title>
<source/>Metabolomics
          <volume>6</volume>
<issue>1</issue>
<year>2010</year>
<fpage>156</fpage>
<lpage>163</lpage>
</element-citation>
</ref>
<ref id="bib97">
<label>97</label>
<element-citation id="sbref88" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kim</surname>
<given-names>Y.</given-names>
</name>
</person-group>
<article-title>Multivariate classification of urine metabolome profiles for breast cancer diagnosis</article-title>
<source/>BMC Bioinform.
          <volume>11</volume>
<issue>2</issue>
<year>2010</year>
<fpage>S4</fpage>
</element-citation>
</ref>
<ref id="bib98">
<label>98</label>
<element-citation id="sbref89" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhai</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>Serum branched-chain amino acid to histidine ratio: a novel metabolomic biomarker of knee osteoarthritis</article-title>
<source/>Ann. Rheum. Dis.
          <volume>69</volume>
<issue>6</issue>
<year>2010</year>
<fpage>1227</fpage>
<lpage>1231</lpage>
<pub-id pub-id-type="pmid">20388742</pub-id>
</element-citation>
</ref>
<ref id="bib99">
<label>99</label>
<element-citation id="sbref90" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>N.-J.</given-names>
</name>
</person-group>
<article-title>Plasma metabolic profiling of Alzheimer's disease by liquid chromatography/mass spectrometry</article-title>
<source/>Clin. Biochem.
          <volume>43</volume>
<issue>12</issue>
<year>2010</year>
<fpage>992</fpage>
<lpage>997</lpage>
<pub-id pub-id-type="pmid">20457143</pub-id>
</element-citation>
</ref>
<ref id="bib100">
<label>100</label>
<element-citation id="sbref91" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zira</surname>
<given-names>A.N.</given-names>
</name>
</person-group>
<article-title><sup>1</sup>H NMR metabonomic analysis in renal cell carcinoma: a possible diagnostic tool</article-title>
<source/>J. Proteome Res.
          <volume>9</volume>
<issue>8</issue>
<year>2010</year>
<fpage>4038</fpage>
<lpage>4044</lpage>
<pub-id pub-id-type="pmid">20527959</pub-id>
</element-citation>
</ref>
<ref id="bib101">
<label>101</label>
<element-citation id="sbref92" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Barnes</surname>
<given-names>V.M.</given-names>
</name>
</person-group>
<article-title>Assessment of the effects of dentifrice on periodontal disease biomarkers in gingival crevicular fluid</article-title>
<source/>J. Periodontol.
          <volume>81</volume>
<issue>9</issue>
<year>2010</year>
<fpage>1273</fpage>
<lpage>1279</lpage>
<pub-id pub-id-type="pmid">20450373</pub-id>
</element-citation>
</ref>
<ref id="bib102">
<label>102</label>
<element-citation id="sbref93" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lauridsen</surname>
<given-names>M.B.</given-names>
</name>
</person-group>
<article-title><sup>1</sup>H NMR spectroscopy-based interventional metabolic phenotyping: a cohort study of rheumatoid arthritis patients</article-title>
<source/>J. Proteome Res.
          <volume>9</volume>
<issue>9</issue>
<year>2010</year>
<fpage>4545</fpage>
<lpage>4553</lpage>
<pub-id pub-id-type="pmid">20701312</pub-id>
</element-citation>
</ref>
<ref id="bib103">
<label>103</label>
<element-citation id="sbref94" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>X.</given-names>
</name>
</person-group>
<article-title>Plasma metabolomics reveals biomarkers of the atherosclerosis</article-title>
<source/>J. Sep. Sci.
          <volume>33</volume>
<issue>17–18</issue>
<year>2010</year>
<fpage>2776</fpage>
<lpage>2783</lpage>
<pub-id pub-id-type="pmid">20730840</pub-id>
</element-citation>
</ref>
<ref id="bib104">
<label>104</label>
<element-citation id="sbref95" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>L.</given-names>
</name>
</person-group>
<article-title>Development and validation of a liquid chromatography–mass spectrometry metabonomic platform in human plasma of liver failure caused by hepatitis B virus</article-title>
<source/>Acta Biochim. Biophys. Sin.
          <volume>42</volume>
<issue>10</issue>
<year>2010</year>
<fpage>688</fpage>
<lpage>698</lpage>
<pub-id pub-id-type="pmid">20810534</pub-id>
</element-citation>
</ref>
<ref id="bib105">
<label>105</label>
<element-citation id="sbref96" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Denery</surname>
<given-names>J.R.</given-names>
</name>
</person-group>
<article-title>Metabolomics-based discovery of diagnostic biomarkers for onchocerciasis</article-title>
<source/>PLoS Negl. Trop. Dis.
          <volume>4</volume>
<issue>10</issue>
<year>2010</year>
<fpage>e834</fpage>
<pub-id pub-id-type="pmid">20957145</pub-id>
</element-citation>
</ref>
<ref id="bib106">
<label>106</label>
<element-citation id="sbref97" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Suhre</surname>
<given-names>K.</given-names>
</name>
</person-group>
<article-title>Metabolic footprint of diabetes: a multiplatform metabolomics study in an epidemiological setting</article-title>
<source/>PLoS One
          <volume>5</volume>
<issue>11</issue>
<year>2010</year>
<fpage>e13953</fpage>
<pub-id pub-id-type="pmid">21085649</pub-id>
</element-citation>
</ref>
<ref id="bib107">
<label>107</label>
<element-citation id="sbref98" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Romero</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>Metabolomics in premature labor: a novel approach to identify patients at risk for preterm delivery</article-title>
<source/>J. Matern. Fetal Neonatal Med.
          <volume>23</volume>
<issue>12</issue>
<year>2010</year>
<fpage>1344</fpage>
<lpage>1359</lpage>
<pub-id pub-id-type="pmid">20504069</pub-id>
</element-citation>
</ref>
<ref id="bib108">
<label>108</label>
<element-citation id="sbref99" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dong</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Lysophosphatidylcholine profiling of plasma: discrimination of isomers and discovery of lung cancer biomarkers</article-title>
<source/>Metabolomics
          <volume>6</volume>
<issue>4</issue>
<year>2010</year>
<fpage>478</fpage>
<lpage>488</lpage>
</element-citation>
</ref>
<ref id="bib109">
<label>109</label>
<element-citation id="sbref100" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Madsen</surname>
<given-names>R.K.</given-names>
</name>
</person-group>
<article-title>Diagnostic properties of metabolic perturbations in rheumatoid arthritis</article-title>
<source/>Arthritis Res. Ther.
          <volume>13</volume>
<issue>1</issue>
<year>2011</year>
<fpage>R19</fpage>
<pub-id pub-id-type="pmid">21303541</pub-id>
</element-citation>
</ref>
<ref id="bib110">
<label>110</label>
<element-citation id="sbref101" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Saude</surname>
<given-names>E.J.</given-names>
</name>
</person-group>
<article-title>Metabolomic profiling of asthma: diagnostic utility of urine nuclear magnetic resonance spectroscopy</article-title>
<source/>J. Allergy Clin. Immunol.
          <volume>127</volume>
<issue>3</issue>
<year>2011</year>
<fpage>757</fpage>
<lpage>764</lpage>
<comment>(e6)</comment>
<pub-id pub-id-type="pmid">21377043</pub-id>
</element-citation>
</ref>
<ref id="bib111">
<label>111</label>
<element-citation id="sbref102" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Han</surname>
<given-names>L.-D.</given-names>
</name>
</person-group>
<article-title>Plasma esterified and non-esterified fatty acids metabolic profiling using gas chromatography–mass spectrometry and its application in the study of diabetic mellitus and diabetic nephropathy</article-title>
<source/>Anal. Chim. Acta
          <volume>689</volume>
<issue>1</issue>
<year>2011</year>
<fpage>85</fpage>
<lpage>91</lpage>
<pub-id pub-id-type="pmid">21338761</pub-id>
</element-citation>
</ref>
<ref id="bib112">
<label>112</label>
<element-citation id="sbref103" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Serum 27-nor-5β-cholestane-3,7,12,24,25 pentol glucuronide discovered by metabolomics as potential diagnostic biomarker for epithelium ovarian cancer</article-title>
<source/>J. Proteome Res.
          <volume>10</volume>
<issue>5</issue>
<year>2011</year>
<fpage>2625</fpage>
<lpage>2632</lpage>
<pub-id pub-id-type="pmid">21456628</pub-id>
</element-citation>
</ref>
<ref id="bib113">
<label>113</label>
<element-citation id="sbref104" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lian</surname>
<given-names>J.S.</given-names>
</name>
</person-group>
<article-title>A serum metabonomic study on the difference between alcohol- and HBV-induced liver cirrhosis by ultraperformance liquid chromatography coupled to mass spectrometry plus quadrupole time-of-flight mass spectrometry</article-title>
<source/>Chin. Med. J.
          <volume>124</volume>
<issue>9</issue>
<year>2011</year>
<fpage>1367</fpage>
<lpage>1373</lpage>
<pub-id pub-id-type="pmid">21740750</pub-id>
</element-citation>
</ref>
<ref id="bib114">
<label>114</label>
<element-citation id="sbref105" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fong</surname>
<given-names>M.Y.</given-names>
</name>
<name>
<surname>McDunn</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Kakar</surname>
<given-names>S.S.</given-names>
</name>
</person-group>
<article-title>Identification of metabolites in the normal ovary and their transformation in primary and metastatic ovarian cancer</article-title>
<source/>PLoS One
          <volume>6</volume>
<issue>5</issue>
<year>2011</year>
<fpage>e19963</fpage>
<pub-id pub-id-type="pmid">21625518</pub-id>
</element-citation>
</ref>
<ref id="bib115">
<label>115</label>
<element-citation id="sbref106" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tang</surname>
<given-names>F.</given-names>
</name>
</person-group>
<article-title>Novel potential markers of nasopharyngeal carcinoma for diagnosis and therapy</article-title>
<source/>Clin. Biochem.
          <volume>44</volume>
<issue>8–9</issue>
<year>2011</year>
<fpage>711</fpage>
<lpage>718</lpage>
<pub-id pub-id-type="pmid">21402064</pub-id>
</element-citation>
</ref>
<ref id="bib116">
<label>116</label>
<element-citation id="sbref107" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>T.</given-names>
</name>
</person-group>
<article-title>Serum and urine metabolite profiling reveals potential biomarkers of human hepatocellular carcinoma</article-title>
<source/>Mol. Cell. Proteom.
          <volume>10</volume>
<issue>7</issue>
<year>2011</year>
</element-citation>
</ref>
<ref id="bib117">
<label>117</label>
<element-citation id="sbref108" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kondo</surname>
<given-names>Y.</given-names>
</name>
</person-group>
<article-title>Serum fatty acid profiling of colorectal cancer by gas chromatography/mass spectrometry</article-title>
<source/>Biomark. Med.
          <volume>5</volume>
<issue>4</issue>
<year>2011</year>
<fpage>451</fpage>
<lpage>460</lpage>
<pub-id pub-id-type="pmid">21861667</pub-id>
</element-citation>
</ref>
<ref id="bib118">
<label>118</label>
<element-citation id="sbref109" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Al-Mubarak</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>Serum metabolomics reveals higher levels of polyunsaturated fatty acids in lepromatous leprosy: potential markers for susceptibility and pathogenesis</article-title>
<source/>PLoS Negl. Trop. Dis.
          <volume>5</volume>
<issue>9</issue>
<year>2011</year>
<fpage>e1303</fpage>
<pub-id pub-id-type="pmid">21909445</pub-id>
</element-citation>
</ref>
<ref id="bib119">
<label>119</label>
<element-citation id="sbref110" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Munshi</surname>
<given-names>S.U.</given-names>
</name>
</person-group>
<article-title>Metabonomic analysis of hepatitis E patients shows deregulated metabolic cycles and abnormalities in amino acid metabolism</article-title>
<source/>J. Viral Hepat.
          <volume>18</volume>
<issue>10</issue>
<year>2011</year>
<fpage>e591</fpage>
<lpage>e602</lpage>
<pub-id pub-id-type="pmid">21914081</pub-id>
</element-citation>
</ref>
<ref id="bib120">
<label>120</label>
<element-citation id="sbref111" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Atzori</surname>
<given-names>L.</given-names>
</name>
</person-group>
<article-title>Clinical metabolomics and urinary NGAL for the early prediction of chronic kidney disease in healthy adults born ELBW</article-title>
<source/>J. Matern. Fetal Neonatal. Med.
          <volume>24</volume>
<issue>sup. 2</issue>
<year>2011</year>
<fpage>40</fpage>
<lpage>43</lpage>
<pub-id pub-id-type="pmid">21781002</pub-id>
</element-citation>
</ref>
<ref id="bib121">
<label>121</label>
<element-citation id="sbref112" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>F.</given-names>
</name>
</person-group>
<article-title>Identification of serum biomarkers of hepatocarcinoma through liquid chromatography/mass spectrometry-based metabonomic method</article-title>
<source/>Anal. Bioanal. Chem.
          <volume>401</volume>
<issue>6</issue>
<year>2011</year>
<fpage>1899</fpage>
<pub-id pub-id-type="pmid">21833635</pub-id>
</element-citation>
</ref>
<ref id="bib122">
<label>122</label>
<element-citation id="sbref113" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hori</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>A metabolomic approach to lung cancer</article-title>
<source/>Lung Cancer
          <volume>74</volume>
<issue>2</issue>
<year>2011</year>
<fpage>284</fpage>
<lpage>292</lpage>
<pub-id pub-id-type="pmid">21411176</pub-id>
</element-citation>
</ref>
<ref id="bib123">
<label>123</label>
<element-citation id="sbref114" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Duan</surname>
<given-names>H.</given-names>
</name>
</person-group>
<article-title>Identification of biomarkers for melamine-induced nephrolithiasis in young children based on ultra high performance liquid chromatography coupled to time-of-flight mass spectrometry (U-HPLC–Q-TOF/MS)</article-title>
<source/>J. Chromatogr. B
          <volume>879</volume>
<issue>30</issue>
<year>2011</year>
<fpage>3544</fpage>
<lpage>3550</lpage>
</element-citation>
</ref>
<ref id="bib124">
<label>124</label>
<element-citation id="sbref115" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Arlt</surname>
<given-names>W.</given-names>
</name>
</person-group>
<article-title>Urine steroid metabolomics as a biomarker tool for detecting malignancy in adrenal tumors</article-title>
<source/>J. Clin. Endocrinol. Metab.
          <volume>96</volume>
<issue>12</issue>
<year>2011</year>
<fpage>3775</fpage>
<lpage>3784</lpage>
<pub-id pub-id-type="pmid">21917861</pub-id>
</element-citation>
</ref>
<ref id="bib125">
<label>125</label>
<element-citation id="sbref116" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Putluri</surname>
<given-names>N.</given-names>
</name>
</person-group>
<article-title>Metabolomic profiling reveals potential markers and bioprocesses altered in bladder cancer progression</article-title>
<source/>Cancer Res.
          <volume>71</volume>
<issue>24</issue>
<year>2011</year>
<fpage>7376</fpage>
<lpage>7386</lpage>
<pub-id pub-id-type="pmid">21990318</pub-id>
</element-citation>
</ref>
<ref id="bib126">
<label>126</label>
<element-citation id="sbref117" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shah</surname>
<given-names>S.H.</given-names>
</name>
</person-group>
<article-title>Baseline metabolomic profiles predict cardiovascular events in patients at risk for coronary artery disease</article-title>
<source/>Am. Heart J.
          <volume>163</volume>
<issue>5</issue>
<year>2012</year>
<comment>(844-+)</comment>
</element-citation>
</ref>
<ref id="bib127">
<label>127</label>
<element-citation id="sbref118" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sato</surname>
<given-names>Y.</given-names>
</name>
</person-group>
<article-title>Identification of a new plasma biomarker of Alzheimer's disease using metabolomics technology</article-title>
<source/>J. Lipid Res.
          <volume>53</volume>
<issue>3</issue>
<year>2012</year>
<fpage>567</fpage>
<lpage>576</lpage>
<pub-id pub-id-type="pmid">22203775</pub-id>
</element-citation>
</ref>
<ref id="bib128">
<label>128</label>
<element-citation id="sbref119" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>van der Kloet</surname>
<given-names>F.M.</given-names>
</name>
</person-group>
<article-title>Discovery of early-stage biomarkers for diabetic kidney disease using ms-based metabolomics (FinnDiane study)</article-title>
<source/>Metabolomics
          <volume>8</volume>
<issue>1</issue>
<year>2012</year>
<fpage>109</fpage>
<lpage>119</lpage>
<pub-id pub-id-type="pmid">22279428</pub-id>
</element-citation>
</ref>
<ref id="bib129">
<label>129</label>
<element-citation id="sbref120" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ikeda</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Serum metabolomics as a novel diagnostic approach for gastrointestinal cancer</article-title>
<source/>Biomed. Chromatogr.
          <volume>26</volume>
<issue>5</issue>
<year>2012</year>
<fpage>548</fpage>
<lpage>558</lpage>
<pub-id pub-id-type="pmid">21773981</pub-id>
</element-citation>
</ref>
<ref id="bib130">
<label>130</label>
<element-citation id="sbref121" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schmerler</surname>
<given-names>D.</given-names>
</name>
</person-group>
<article-title>Targeted metabolomics for discrimination of systemic inflammatory disorders in critically ill patients</article-title>
<source/>J. Lipid Res.
          <volume>53</volume>
<issue>7</issue>
<year>2012</year>
<fpage>1369</fpage>
<lpage>1375</lpage>
<pub-id pub-id-type="pmid">22581935</pub-id>
</element-citation>
</ref>
<ref id="bib131">
<label>131</label>
<element-citation id="sbref122" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>T.</given-names>
</name>
</person-group>
<article-title>Discrimination between malignant and benign ovarian tumors by plasma metabolomic profiling using ultra performance liquid chromatography/mass spectrometry</article-title>
<source/>Clin. Chim. Acta
          <volume>413</volume>
<issue>9–10</issue>
<year>2012</year>
<fpage>861</fpage>
<lpage>868</lpage>
<pub-id pub-id-type="pmid">22309680</pub-id>
</element-citation>
</ref>
<ref id="bib132">
<label>132</label>
<element-citation id="sbref123" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sun</surname>
<given-names>J.C.</given-names>
</name>
</person-group>
<article-title>Serum metabolomic profiles from patients with acute kidney injury: a pilot study</article-title>
<source/>J. Chromatogr. B-Anal. Technol. Biomed. Life Sci.
          <volume>893</volume>
<year>2012</year>
<fpage>107</fpage>
<lpage>113</lpage>
</element-citation>
</ref>
<ref id="bib133">
<label>133</label>
<element-citation id="sbref124" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vouk</surname>
<given-names>K.</given-names>
</name>
</person-group>
<article-title>Discovery of phosphatidylcholines and sphingomyelins as biomarkers for ovarian endometriosis</article-title>
<source/>Hum. Reprod.
          <volume>27</volume>
<issue>10</issue>
<year>2012</year>
<fpage>2955</fpage>
<lpage>2965</lpage>
<pub-id pub-id-type="pmid">22859507</pub-id>
</element-citation>
</ref>
<ref id="bib134">
<label>134</label>
<element-citation id="sbref125" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lv</surname>
<given-names>W.W.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>T.S.</given-names>
</name>
</person-group>
<article-title>Identification of possible biomarkers for breast cancer from free fatty acid profiles determined by GC-MS and multivariate statistical analysis</article-title>
<source/>Clin. Biochem.
          <volume>45</volume>
<issue>1–2</issue>
<year>2012</year>
<fpage>127</fpage>
<lpage>133</lpage>
<pub-id pub-id-type="pmid">22061338</pub-id>
</element-citation>
</ref>
<ref id="bib135">
<label>135</label>
<element-citation id="sbref126" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xu</surname>
<given-names>H.B.</given-names>
</name>
</person-group>
<article-title>Potential clinical utility of plasma amino acid profiling in the detection of major depressive disorder</article-title>
<source/>Psychiatry Res.
          <volume>200</volume>
<issue>2–3</issue>
<year>2012</year>
<fpage>1054</fpage>
<lpage>1057</lpage>
<pub-id pub-id-type="pmid">22749229</pub-id>
</element-citation>
</ref>
<ref id="bib136">
<label>136</label>
<element-citation id="sbref127" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Menni</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>Biomarkers for type 2 diabetes and impaired fasting glucose using a nontargeted metabolomics approach</article-title>
<source/>Diabetes
          <volume>62</volume>
<issue>12</issue>
<year>2013</year>
<fpage>4270</fpage>
<lpage>4276</lpage>
<pub-id pub-id-type="pmid">23884885</pub-id>
</element-citation>
</ref>
<ref id="bib137">
<label>137</label>
<element-citation id="sbref128" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Potential metabolite markers of schizophrenia</article-title>
<source/>Mol. Psychiatry
          <volume>18</volume>
<issue>1</issue>
<year>2013</year>
<fpage>67</fpage>
<lpage>78</lpage>
<pub-id pub-id-type="pmid">22024767</pub-id>
</element-citation>
</ref>
<ref id="bib138">
<label>138</label>
<element-citation id="sbref129" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>McDunn</surname>
<given-names>J.E.</given-names>
</name>
</person-group>
<article-title>Metabolomic signatures of aggressive prostate cancer</article-title>
<source/>Prostate
          <volume>73</volume>
<issue>14</issue>
<year>2013</year>
<fpage>1547</fpage>
<lpage>1560</lpage>
<pub-id pub-id-type="pmid">23824564</pub-id>
</element-citation>
</ref>
<ref id="bib139">
<label>139</label>
<element-citation id="sbref130" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jung</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Serum metabolomics reveals pathways and biomarkers associated with asthma pathogenesis</article-title>
<source/>Clin. Exp. Allergy
          <volume>43</volume>
<issue>4</issue>
<year>2013</year>
<fpage>425</fpage>
<lpage>433</lpage>
<pub-id pub-id-type="pmid">23517038</pub-id>
</element-citation>
</ref>
<ref id="bib140">
<label>140</label>
<element-citation id="sbref131" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>A.H.</given-names>
</name>
</person-group>
<article-title>Urinary metabolic biomarker and pathway study of hepatitis B virus infected patients based on UPLC-MS system</article-title>
<source/>PLoS One
          <volume>8</volume>
<issue>5</issue>
<year>2013</year>
</element-citation>
</ref>
<ref id="bib141">
<label>141</label>
<element-citation id="sbref132" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>L.</given-names>
</name>
</person-group>
<article-title>H-1-NMR based metabonomic profiling of human esophageal cancer tissue</article-title>
<source/>Mol. Cancer
          <year>2013</year>
<fpage>12</fpage>
<pub-id pub-id-type="pmid">23409748</pub-id>
</element-citation>
</ref>
<ref id="bib142">
<label>142</label>
<element-citation id="sbref133" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>H.J.</given-names>
</name>
</person-group>
<article-title>H-1 NMR-based metabolic profiling of human rectal cancer tissue</article-title>
<source/>Mol. Cancer
          <year>2013</year>
<fpage>12</fpage>
<pub-id pub-id-type="pmid">23409748</pub-id>
</element-citation>
</ref>
<ref id="bib143">
<label>143</label>
<element-citation id="sbref134" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Metabolomic identification of diagnostic plasma biomarkers in humans with chronic heart failure</article-title>
<source/>Mol. Biosyst.
          <volume>9</volume>
<issue>11</issue>
<year>2013</year>
<fpage>2618</fpage>
<lpage>2626</lpage>
<pub-id pub-id-type="pmid">23959290</pub-id>
</element-citation>
</ref>
<ref id="bib144">
<label>144</label>
<element-citation id="sbref135" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>Identification of plasma metabolomic profiling for diagnosis of esophageal squamous-cell carcinoma using an UPLC/TOF/MS platform</article-title>
<source/>Int. J. Mol. Sci.
          <volume>14</volume>
<issue>5</issue>
<year>2013</year>
<fpage>8899</fpage>
<lpage>8911</lpage>
<pub-id pub-id-type="pmid">23615477</pub-id>
</element-citation>
</ref>
<ref id="bib145">
<label>145</label>
<element-citation id="sbref136" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rizza</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Metabolomics signature improves the prediction of cardiovascular events in elderly subjects</article-title>
<source/>Atherosclerosis
          <volume>232</volume>
<issue>2</issue>
<year>2014</year>
<fpage>260</fpage>
<lpage>264</lpage>
<pub-id pub-id-type="pmid">24468136</pub-id>
</element-citation>
</ref>
<ref id="bib146">
<label>146</label>
<element-citation id="sbref137" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jin</surname>
<given-names>X.</given-names>
</name>
</person-group>
<article-title>Diagnosis of bladder cancer and prediction of survival by urinary metabolomics</article-title>
<source/>Oncotarget
          <volume>5</volume>
<issue>6</issue>
<year>2014</year>
<fpage>1635</fpage>
<lpage>1645</lpage>
<pub-id pub-id-type="pmid">24721970</pub-id>
</element-citation>
</ref>
<ref id="bib147">
<label>147</label>
<element-citation id="sbref138" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dawiskiba</surname>
<given-names>T.</given-names>
</name>
</person-group>
<article-title>Serum and urine metabolomic fingerprinting in diagnostics of inflammatory bowel diseases</article-title>
<source/>World J. Gastroenterol.
          <volume>20</volume>
<issue>1</issue>
<year>2014</year>
<fpage>163</fpage>
<lpage>174</lpage>
<pub-id pub-id-type="pmid">24415869</pub-id>
</element-citation>
</ref>
<ref id="bib148">
<label>148</label>
<element-citation id="sbref139" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>Plasma metabolite profiles of Alzheimer's disease and mild cognitive impairment</article-title>
<source/>J. Proteome Res.
          <volume>13</volume>
<issue>5</issue>
<year>2014</year>
<fpage>2649</fpage>
<lpage>2658</lpage>
<pub-id pub-id-type="pmid">24694177</pub-id>
</element-citation>
</ref>
<ref id="bib149">
<label>149</label>
<element-citation id="sbref140" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mathe</surname>
<given-names>E.A.</given-names>
</name>
</person-group>
<article-title>Noninvasive urinary metabolomic profiling identifies diagnostic and prognostic markers in lung cancer</article-title>
<source/>Cancer Res.
          <volume>74</volume>
<issue>12</issue>
<year>2014</year>
<fpage>3259</fpage>
<lpage>3270</lpage>
<pub-id pub-id-type="pmid">24736543</pub-id>
</element-citation>
</ref>
<ref id="bib150">
<label>150</label>
<element-citation id="sbref141" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Reinke</surname>
<given-names>S.N.</given-names>
</name>
</person-group>
<article-title>Metabolomic profiling in multiple sclerosis: insights into biomarkers and pathogenesis</article-title>
<source/>Mult. Scler.
          <volume>20</volume>
<issue>10</issue>
<year>2014</year>
<fpage>1396</fpage>
<lpage>1400</lpage>
<pub-id pub-id-type="pmid">24468817</pub-id>
</element-citation>
</ref>
<ref id="bib151">
<label>151</label>
<element-citation id="sbref142" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Graham</surname>
<given-names>S.F.</given-names>
</name>
<name>
<surname>Holscher</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Green</surname>
<given-names>B.D.</given-names>
</name>
</person-group>
<article-title>Metabolic signatures of human Alzheimer's disease (AD): H-1 NMR analysis of the polar metabolome of post-mortem brain tissue</article-title>
<source/>Metabolomics
          <volume>10</volume>
<issue>4</issue>
<year>2014</year>
<fpage>744</fpage>
<lpage>753</lpage>
</element-citation>
</ref>
<ref id="bib152">
<label>152</label>
<element-citation id="sbref143" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>Q.</given-names>
</name>
</person-group>
<article-title>Measurement of salivary metabolite biomarkers for early monitoring of oral cancer with ultra performance liquid chromatography-mass spectrometry</article-title>
<source/>Talanta
          <volume>119</volume>
<year>2014</year>
<fpage>299</fpage>
<lpage>305</lpage>
<pub-id pub-id-type="pmid">24401418</pub-id>
</element-citation>
</ref>
<ref id="bib153">
<label>153</label>
<element-citation id="sbref144" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>X.</given-names>
</name>
</person-group>
<article-title>Discovery and validation of plasma biomarkers for major depressive disorder classification based on liquid chromatography-mass spectrometry</article-title>
<source/>J. Proteome Res.
          <volume>14</volume>
<issue>5</issue>
<year>2015</year>
<fpage>2322</fpage>
<lpage>2330</lpage>
<pub-id pub-id-type="pmid">25784130</pub-id>
</element-citation>
</ref>
<ref id="bib154">
<label>154</label>
<element-citation id="sbref145" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Drogan</surname>
<given-names>D.</given-names>
</name>
</person-group>
<article-title>Untargeted metabolic profiling identifies altered serum metabolites of type 2 diabetes mellitus in a prospective, nested case control study</article-title>
<source/>Clin. Chem.
          <volume>61</volume>
<issue>3</issue>
<year>2015</year>
<fpage>487</fpage>
<lpage>497</lpage>
<pub-id pub-id-type="pmid">25524438</pub-id>
</element-citation>
</ref>
<ref id="bib155">
<label>155</label>
<element-citation id="sbref146" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Calderon-Santiago</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Human sweat metabolomics for lung cancer screening</article-title>
<source/>Anal. Bioanal. Chem.
          <volume>407</volume>
<issue>18</issue>
<year>2015</year>
<fpage>5381</fpage>
<lpage>5392</lpage>
<pub-id pub-id-type="pmid">25935675</pub-id>
</element-citation>
</ref>
<ref id="bib156">
<label>156</label>
<element-citation id="sbref147" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pieragostino</surname>
<given-names>D.</given-names>
</name>
</person-group>
<article-title>An integrated metabolomics approach for the research of new cerebrospinal fluid biomarkers of multiple sclerosis</article-title>
<source/>Mol. Biosyst.
          <volume>11</volume>
<issue>6</issue>
<year>2015</year>
<fpage>1563</fpage>
<lpage>1572</lpage>
<pub-id pub-id-type="pmid">25690641</pub-id>
</element-citation>
</ref>
<ref id="bib157">
<label>157</label>
<element-citation id="sbref148" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Miyamoto</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Systemic metabolomic changes in blood samples of lung cancer patients identified by gas chromatography time-of-flight mass spectrometry</article-title>
<source/>Metabolites
          <volume>5</volume>
<issue>2</issue>
<year>2015</year>
<fpage>192</fpage>
<lpage>210</lpage>
<pub-id pub-id-type="pmid">25859693</pub-id>
</element-citation>
</ref>
<ref id="bib158">
<label>158</label>
<element-citation id="sbref149" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Luan</surname>
<given-names>H.</given-names>
</name>
</person-group>
<article-title>LC-MS-based urinary metabolite signatures in idiopathic Parkinson's disease</article-title>
<source/>J. Proteome Res.
          <volume>14</volume>
<issue>1</issue>
<year>2015</year>
<fpage>467</fpage>
<lpage>478</lpage>
<pub-id pub-id-type="pmid">25271123</pub-id>
</element-citation>
</ref>
<ref id="bib159">
<label>159</label>
<element-citation id="sbref150" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Trivedi</surname>
<given-names>D.K.</given-names>
</name>
<name>
<surname>Iles</surname>
<given-names>R.K.</given-names>
</name>
</person-group>
<article-title>Shotgun metabolomic profiles in maternal urine identify potential mass spectral markers of abnormal fetal biochemistry – dihydrouracil and progesterone in the metabolism of Down syndrome</article-title>
<source/>Biomed. Chromatogr.
          <volume>29</volume>
<issue>8</issue>
<year>2015</year>
<fpage>1173</fpage>
<lpage>1183</lpage>
<pub-id pub-id-type="pmid">25545476</pub-id>
</element-citation>
</ref>
<ref id="bib160">
<label>160</label>
<element-citation id="sbref151" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Livshits</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>An omics investigation into chronic widespread musculoskeletal pain reveals epiandrosterone sulfate as a potential biomarker</article-title>
<source/>Pain
          <volume>156</volume>
<issue>10</issue>
<year>2015</year>
<fpage>1845</fpage>
<lpage>1851</lpage>
<pub-id pub-id-type="pmid">25915148</pub-id>
</element-citation>
</ref>
<ref id="bib161">
<label>161</label>
<element-citation id="sbref152" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dieme</surname>
<given-names>B.</given-names>
</name>
</person-group>
<article-title>Metabolomics study of urine in autism spectrum disorders using a multiplatform analytical methodology</article-title>
<source/>J. Proteome Res.
          <volume>14</volume>
<issue>12</issue>
<year>2015</year>
<fpage>5273</fpage>
<lpage>5282</lpage>
<pub-id pub-id-type="pmid">26538324</pub-id>
</element-citation>
</ref>
<ref id="bib162">
<label>162</label>
<element-citation id="sbref153" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Guo</surname>
<given-names>L.</given-names>
</name>
</person-group>
<article-title>Three plasma metabolite signatures for diagnosing high altitude pulmonary edema</article-title>
<source/>Sci. Rep.
          <volume>5</volume>
<year>2015</year>
</element-citation>
</ref>
<ref id="bib163">
<label>163</label>
<element-citation id="sbref154" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Venter</surname>
<given-names>L.</given-names>
</name>
</person-group>
<article-title>Untargeted urine metabolomics reveals a biosignature for muscle respiratory chain deficiencies</article-title>
<source/>Metabolomics
          <volume>11</volume>
<issue>1</issue>
<year>2015</year>
<fpage>111</fpage>
<lpage>121</lpage>
</element-citation>
</ref>
<ref id="bib164">
<label>164</label>
<element-citation id="sbref155" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liang</surname>
<given-names>Q.</given-names>
</name>
</person-group>
<article-title>Metabolomics-based screening of salivary biomarkers for early diagnosis of Alzheimer's disease</article-title>
<source/>RSC Adv.
          <volume>5</volume>
<issue>116</issue>
<year>2015</year>
<fpage>96074</fpage>
<lpage>96079</lpage>
</element-citation>
</ref>
<ref id="bib165">
<label>165</label>
<element-citation id="sbref156" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Embade</surname>
<given-names>N.</given-names>
</name>
</person-group>
<article-title>Metabolic characterization of advanced liver fibrosis in HCV patients as studied by serum H-1-NMR spectroscopy</article-title>
<source/>PLoS One
          <volume>11</volume>
<issue>5</issue>
<year>2016</year>
</element-citation>
</ref>
<ref id="bib166">
<label>166</label>
<element-citation id="sbref157" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chan</surname>
<given-names>A.W.</given-names>
</name>
</person-group>
<article-title>H-1-NMR urinary metabolomic profiling for diagnosis of gastric cancer</article-title>
<source/>Br. J. Cancer
          <volume>114</volume>
<issue>1</issue>
<year>2016</year>
<fpage>59</fpage>
<lpage>62</lpage>
<pub-id pub-id-type="pmid">26645240</pub-id>
</element-citation>
</ref>
<ref id="bib167">
<label>167</label>
<element-citation id="sbref158" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cameron</surname>
<given-names>S.J.S.</given-names>
</name>
</person-group>
<article-title>The metabolomic detection of lung cancer biomarkers in sputum</article-title>
<source/>Lung Cancer
          <volume>94</volume>
<year>2016</year>
<fpage>88</fpage>
<lpage>95</lpage>
<pub-id pub-id-type="pmid">26973212</pub-id>
</element-citation>
</ref>
<ref id="bib168">
<label>168</label>
<element-citation id="sbref159" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Di Gangi</surname>
<given-names>I.M.</given-names>
</name>
</person-group>
<article-title>Metabolomic profile in pancreatic cancer patients: a consensus-based approach to identify highly discriminating metabolites</article-title>
<source/>Oncotarget
          <volume>7</volume>
<issue>5</issue>
<year>2016</year>
<fpage>5815</fpage>
<lpage>5829</lpage>
<pub-id pub-id-type="pmid">26735340</pub-id>
</element-citation>
</ref>
<ref id="bib169">
<label>169</label>
<element-citation id="sbref160" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>H.</given-names>
</name>
</person-group>
<article-title>Potential serum biomarkers from a metabolomics study of autism</article-title>
<source/>J. Psychiatry Neurosci.
          <volume>41</volume>
<issue>1</issue>
<year>2016</year>
<fpage>27</fpage>
<lpage>37</lpage>
<pub-id pub-id-type="pmid">26395811</pub-id>
</element-citation>
</ref>
<ref id="bib170">
<label>170</label>
<element-citation id="sbref161" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Farshidfar</surname>
<given-names>F.</given-names>
</name>
</person-group>
<article-title>A validated metabolomic signature for colorectal cancer: exploration of the clinical value of metabolomics</article-title>
<source/>Br. J. Cancer
          <volume>115</volume>
<issue>7</issue>
<year>2016</year>
<fpage>848</fpage>
<lpage>857</lpage>
<pub-id pub-id-type="pmid">27560555</pub-id>
</element-citation>
</ref>
<ref id="bib171">
<label>171</label>
<element-citation id="sbref162" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Smolenska</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Smolenski</surname>
<given-names>R.T.</given-names>
</name>
<name>
<surname>Zdrojewski</surname>
<given-names>Z.</given-names>
</name>
</person-group>
<article-title>Plasma concentrations of amino acid and nicotinamide metabolites in rheumatoid arthritis--potential biomarkers of disease activity and drug treatment</article-title>
<source/>Biomarkers
          <volume>21</volume>
<issue>3</issue>
<year>2016</year>
<fpage>218</fpage>
<lpage>224</lpage>
<pub-id pub-id-type="pmid">26811910</pub-id>
</element-citation>
</ref>
<ref id="bib172">
<label>172</label>
<element-citation id="sbref163" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kind</surname>
<given-names>T.</given-names>
</name>
</person-group>
<article-title>Interstitial cystitis-associated urinary metabolites identified by mass-spectrometry based metabolomics analysis</article-title>
<source/>Sci. Rep.
          <volume>6</volume>
<year>2016</year>
<fpage>39227</fpage>
<pub-id pub-id-type="pmid">27976711</pub-id>
</element-citation>
</ref>
<ref id="bib173">
<label>173</label>
<element-citation id="sbref164" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shao</surname>
<given-names>X.</given-names>
</name>
</person-group>
<article-title>Screening and verifying endometrial carcinoma diagnostic biomarkers based on a urine metabolomic profiling study using UPLC-Q-TOF/MS</article-title>
<source/>Clin. Chim. Acta
          <volume>463</volume>
<year>2016</year>
<fpage>200</fpage>
<lpage>206</lpage>
<pub-id pub-id-type="pmid">27784637</pub-id>
</element-citation>
</ref>
<ref id="bib174">
<label>174</label>
<element-citation id="sbref165" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>T.</given-names>
</name>
</person-group>
<article-title>Biomarker identification and pathway analysis of preeclampsia based on serum metabolomics</article-title>
<source/>Biochem. Biophys. Res. Commun.
          <volume>485</volume>
<issue>1</issue>
<year>2017</year>
<fpage>119</fpage>
<lpage>125</lpage>
<pub-id pub-id-type="pmid">28188789</pub-id>
</element-citation>
</ref>
<ref id="bib175">
<label>175</label>
<element-citation id="sbref166" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kang</surname>
<given-names>H.</given-names>
</name>
</person-group>
<article-title>Exploration of candidate biomarkers for human psoriasis based on gas chromatography-mass spectrometry serum metabolomics</article-title>
<source/>Br. J. Dermatol.
          <volume>176</volume>
<issue>3</issue>
<year>2017</year>
<fpage>713</fpage>
<lpage>722</lpage>
<pub-id pub-id-type="pmid">27564527</pub-id>
</element-citation>
</ref>
</ref-list>
<ack id="ack0005">
<title>Acknowledgments</title>
<p>D.K.T. and R.G. thank the Cancer Research UK (including Experimental Cancer Medicine Centre award) for funding. RG also thanks the <funding-source id="gs1">UK Medical Research Council</funding-source> (Grant MRC G1001375/1) and the <funding-source id="gs2">Wellcome Trust</funding-source> (Grant 202952/Z/16/Z) for funding of metabolomics.</p>
</ack>
</back>
</article>
</pmc-articleset>